

# Jason A Roberts

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/583112/publications.pdf>

Version: 2024-02-01

573  
papers

31,801  
citations

5248

83  
h-index

7136

153  
g-index

588  
all docs

588  
docs citations

588  
times ranked

17335  
citing authors

#	ARTICLE	IF	CITATIONS
1	Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. <i>Clinical Infectious Diseases</i> , 2016, 63, e61-e111.	2.9	2,405
2	Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. <i>Intensive Care Medicine</i> , 2021, 47, 1181-1247.	3.9	1,503
3	Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. <i>Critical Care Medicine</i> , 2021, 49, e1063-e1143.	0.4	927
4	DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current $\beta$ -Lactam Antibiotic Doses Sufficient for Critically Ill Patients?. <i>Clinical Infectious Diseases</i> , 2014, 58, 1072-1083.	2.9	843
5	Pharmacokinetic issues for antibiotics in the critically ill patient. <i>Critical Care Medicine</i> , 2009, 37, 840-851.	0.4	755
6	Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 498-509.	4.6	745
7	Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#. <i>Intensive Care Medicine</i> , 2020, 46, 1127-1153.	3.9	504
8	Subtherapeutic Initial $\beta$ -Lactam Concentrations in Select Critically Ill Patients. <i>Chest</i> , 2012, 142, 30-39.	0.4	354
9	Executive Summary: Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. <i>Clinical Infectious Diseases</i> , 2016, 63, 575-582.	2.9	334
10	The Effects of Hypoalbuminaemia on Optimizing Antibacterial Dosing in Critically Ill Patients. <i>Clinical Pharmacokinetics</i> , 2011, 50, 99-110.	1.6	325
11	Continuous Infusion of Beta-Lactam Antibiotics in Severe Sepsis: A Multicenter Double-Blind, Randomized Controlled Trial. <i>Clinical Infectious Diseases</i> , 2013, 56, 236-244.	2.9	317
12	Augmented Renal Clearance. <i>Clinical Pharmacokinetics</i> , 2010, 49, 1-16.	1.6	313
13	Continuous versus Intermittent $\beta$ -Lactam Infusion in Severe Sepsis. A Meta-analysis of Individual Patient Data from Randomized Trials. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 681-691.	2.5	308
14	Therapeutic drug monitoring of $\beta$ -lactams in critically ill patients: proof of concept. <i>International Journal of Antimicrobial Agents</i> , 2010, 36, 332-339.	1.1	305
15	Antibiotic resistance—What's dosing got to do with it?. <i>Critical Care Medicine</i> , 2008, 36, 2433-2440.	0.4	299
16	Isolation and rapid sharing of the 2019 novel coronavirus ( $\langle \text{scp} \rangle$ SARS $\langle / \text{scp} \rangle$ $\hat{a}$ $\langle \text{CoV} \hat{a} \langle \text{e} \rangle$ ) from the first patient diagnosed with $\langle \text{scp} \rangle$ COVID $\langle / \text{scp} \rangle$ $\hat{a}$ $\langle \text{e} \rangle$ 19 in Australia. <i>Medical Journal of Australia</i> , 2020, 212, 459-462.	0.8	297
17	Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 142-150.	1.3	294
18	Effect of Dexmedetomidine Added to Standard Care on Ventilator-Free Time in Patients With Agitated Delirium. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1460.	3.8	289

#	ARTICLE	IF	CITATIONS
19	Obesity in the critically ill: a narrative review. <i>Intensive Care Medicine</i> , 2019, 45, 757-769.	3.9	283
20	Therapeutic drug monitoring of antimicrobials. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 27-36.	1.1	263
21	Pharmacokinetic changes in patients receiving extracorporeal membrane oxygenation. <i>Journal of Critical Care</i> , 2012, 27, 741.e9-741.e18.	1.0	257
22	Antibacterial Dosing in Intensive Care. <i>Clinical Pharmacokinetics</i> , 2006, 45, 755-773.	1.6	247
23	A systematic review on clinical benefits of continuous administration of $\hat{\text{I}}^2$ -lactam antibiotics*. <i>Critical Care Medicine</i> , 2009, 37, 2071-2078.	0.4	244
24	Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis. <i>Intensive Care Medicine</i> , 2016, 42, 1535-1545.	3.9	244
25	Sequestration of drugs in the circuit may lead to therapeutic failure during extracorporeal membrane oxygenation. <i>Critical Care</i> , 2012, 16, R194.	2.5	233
26	The Clinical Relevance of Plasma Protein Binding Changes. <i>Clinical Pharmacokinetics</i> , 2013, 52, 1-8.	1.6	225
27	Executive Summary: Surviving Sepsis Campaign: International Guidelines for the Management of Sepsis and Septic Shock 2021. <i>Critical Care Medicine</i> , 2021, 49, 1974-1982.	0.4	209
28	A Multicenter Randomized Trial of Continuous versus Intermittent $\hat{\text{I}}^2$ -Lactam Infusion in Severe Sepsis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 192, 1298-1305.	2.5	206
29	Vancomycin Dosing in Critically Ill Patients: Robust Methods for Improved Continuous-Infusion Regimens. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 2704-2709.	1.4	197
30	Clinical implications of antibiotic pharmacokinetic principles in the critically ill. <i>Intensive Care Medicine</i> , 2013, 39, 2070-2082.	3.9	192
31	Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy. <i>Critical Care Medicine</i> , 2012, 40, 1523-1528.	0.4	185
32	Protein Binding of $\hat{\text{I}}^2$ -Lactam Antibiotics in Critically Ill Patients: Can We Successfully Predict Unbound Concentrations?. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 6165-6170.	1.4	185
33	An international, multicentre survey of $\hat{\text{A}}$ -lactam antibiotic therapeutic drug monitoring practice in intensive care units. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1416-1423.	1.3	185
34	Protein-bound drugs are prone to sequestration in the extracorporeal membrane oxygenation circuit: results from an ex vivo study. <i>Critical Care</i> , 2015, 19, 164.	2.5	181
35	A comparison of estimates of glomerular filtration in critically ill patients with augmented renal clearance. <i>Critical Care</i> , 2011, 15, R139.	2.5	174
36	Analysis of 12 beta-lactam antibiotics in human plasma by HPLC with ultraviolet detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010, 878, 2039-2043.	1.2	172

#	ARTICLE	IF	CITATIONS
37	Hepatitis and death following vaccination with 17D-204 yellow fever vaccine. <i>Lancet</i> , The, 2001, 358, 121-122.	6.3	170
38	Implications of augmented renal clearance in critically ill patients. <i>Nature Reviews Nephrology</i> , 2011, 7, 539-543.	4.1	169
39	A Systematic Review of the Definitions, Determinants, and Clinical Outcomes of Antimicrobial De-escalation in the Intensive Care Unit. <i>Clinical Infectious Diseases</i> , 2016, 62, 1009-1017.	2.9	168
40	Piperacillin penetration into tissue of critically ill patients with sepsisâ€”Bolus versus continuous administration?. <i>Critical Care Medicine</i> , 2009, 37, 926-933.	0.4	166
41	Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?. <i>Critical Care</i> , 2013, 17, R84.	2.5	166
42	Continuous infusion of $\beta$ -lactam antibiotics in severe infections: a review of its role. <i>International Journal of Antimicrobial Agents</i> , 2007, 30, 11-18.	1.1	161
43	First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. <i>International Journal of Antimicrobial Agents</i> , 2010, 35, 156-163.	1.1	154
44	French legal approach to clinical research. <i>Anaesthesia, Critical Care &amp; Pain Medicine</i> , 2018, 37, 607-614.	0.6	153
45	Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review. <i>Annals of Intensive Care</i> , 2012, 2, 35.	2.2	149
46	Augmented renal clearance in septic and traumatized patients with normal plasma creatinine concentrations: identifying at-risk patients. <i>Critical Care</i> , 2013, 17, R35.	2.5	149
47	Risk factors for target non-attainment during empirical treatment with $\beta$ -lactam antibiotics in critically ill patients. <i>Intensive Care Medicine</i> , 2014, 40, 1340-1351.	3.9	147
48	Applying Pharmacokinetic/Pharmacodynamic Principles in Critically Ill Patients: Optimizing Efficacy and Reducing Resistance Development. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2015, 36, 136-153.	0.8	134
49	Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA). <i>World Journal of Emergency Surgery</i> , 2016, 11, 33.	2.1	130
50	Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 196-207.	1.3	129
51	On-Site Therapeutic Drug Monitoring. <i>Trends in Biotechnology</i> , 2020, 38, 1262-1277.	4.9	128
52	Therapeutic drug monitoring of $\beta$ -lactam antibiotics in the critically ill: direct measurement of unbound drug concentrations to achieve appropriate drug exposures. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 3087-3094.	1.3	124
53	Use of nebulized antimicrobials for the treatment of respiratory infections in invasively mechanically ventilated adults: a position paper from the European Society of Clinical Microbiology and Infectious Diseases. <i>Clinical Microbiology and Infection</i> , 2017, 23, 629-639.	2.8	121
54	Monte Carlo simulations: maximizing antibiotic pharmacokinetic data to optimize clinical practice for critically ill patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 227-231.	1.3	119

#	ARTICLE	IF	CITATIONS
55	Antimicrobial Pharmacokinetic and Pharmacodynamic Issues in the Critically Ill with Severe Sepsis and Septic Shock. <i>Critical Care Clinics</i> , 2011, 27, 19-34.	1.0	118
56	Therapeutic drug monitoring of the $\beta$ -lactam antibiotics: what is the evidence and which patients should we be using it for?: Figure 1. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, dkv201.	1.3	118
57	Is continuous infusion ceftriaxone better than once-a-day dosing in intensive care? A randomized controlled pilot study. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 59, 285-291.	1.3	111
58	Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance?. <i>Critical Care</i> , 2015, 19, 28.	2.5	111
59	Protein-inspired antibiotics active against vancomycin- and daptomycin-resistant bacteria. <i>Nature Communications</i> , 2018, 9, 22.	5.8	111
60	Optimising drug dosing in patients receiving extracorporeal membrane oxygenation. <i>Journal of Thoracic Disease</i> , 2018, 10, S629-S641.	0.6	110
61	A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics. <i>Critical Care</i> , 2015, 19, 84.	2.5	108
62	Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study. <i>Critical Care</i> , 2015, 19, 33.	2.5	108
63	A method for determining the free (unbound) concentration of ten beta-lactam antibiotics in human plasma using high performance liquid chromatography with ultraviolet detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2012, 907, 178-184.	1.2	107
64	Reporting Guidelines for Clinical Pharmacokinetic Studies: The ClinPK Statement. <i>Clinical Pharmacokinetics</i> , 2015, 54, 783-795.	1.6	107
65	The ADMIN-ICU survey: a survey on antimicrobial dosing and monitoring in ICUs. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2671-2677.	1.3	106
66	What Antibiotic Exposures Are Required to Suppress the Emergence of Resistance for Gram-Negative Bacteria? A Systematic Review. <i>Clinical Pharmacokinetics</i> , 2019, 58, 1407-1443.	1.6	106
67	The Impact of Variation in Renal Replacement Therapy Settings on Piperacillin, Meropenem, and Vancomycin Drug Clearance in the Critically Ill. <i>Critical Care Medicine</i> , 2014, 42, 1640-1650.	0.4	103
68	Flucloxacillin dosing in critically ill patients with hypoalbuminaemia: special emphasis on unbound pharmacokinetics. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1771-1778.	1.3	102
69	Augmented renal clearance in critically ill patients: etiology, definition and implications for beta-lactam dose optimization. <i>Current Opinion in Pharmacology</i> , 2015, 24, 1-6.	1.7	101
70	Antimicrobial resistance and antibiotic stewardship programs in the ICU: insistence and persistence in the fight against resistance. A position statement from ESICM/ESCMID/WAAAR round table on multi-drug resistance. <i>Intensive Care Medicine</i> , 2018, 44, 189-196.	3.9	101
71	The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections. <i>Intensive Care Medicine</i> , 2017, 43, 1021-1032.	3.9	100
72	Therapeutic drug monitoring of anti-infective agents in critically ill patients. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 961-979.	1.3	98

#	ARTICLE	IF	CITATIONS
73	Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society Of Infectious Diseases Pharmacists. <i>Clinical Biochemist Reviews</i> , 2010, 31, 21-4.	3.3	98
74	Antimicrobial de-escalation in critically ill patients: a position statement from a task force of the European Society of Intensive Care Medicine (ESICM) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Critically Ill Patients Study Group (ESGCIP). <i>Intensive Care Medicine</i> , 2020, 46, 245-265.	3.9	97
75	Assays for therapeutic drug monitoring of $\beta$ -lactam antibiotics: A structured review. <i>International Journal of Antimicrobial Agents</i> , 2015, 46, 367-375.	1.1	95
76	Vancomycin-Associated Nephrotoxicity in the Critically Ill. <i>Critical Care Medicine</i> , 2014, 42, 2527-2536.	0.4	94
77	Advances in antibiotic therapy in the critically ill. <i>Critical Care</i> , 2016, 20, 133.	2.5	94
78	Effect of obesity on the pharmacokinetics of antimicrobials in critically ill patients: A structured review. <i>International Journal of Antimicrobial Agents</i> , 2016, 47, 259-268.	1.1	94
79	$\beta$ -Lactam pharmacokinetics during extracorporeal membrane oxygenation therapy: A case-control study. <i>International Journal of Antimicrobial Agents</i> , 2015, 45, 278-282.	1.1	93
80	Effect of therapeutic drug monitoring-based dose optimization of piperacillin/tazobactam on sepsis-related organ dysfunction in patients with sepsis: a randomized controlled trial. <i>Intensive Care Medicine</i> , 2022, 48, 311-321.	3.9	91
81	Better outcomes through continuous infusion of time-dependent antibiotics to critically ill patients?. <i>Current Opinion in Critical Care</i> , 2008, 14, 390-396.	1.6	90
82	ASAP ECMO: Antibiotic, Sedative and Analgesic Pharmacokinetics during Extracorporeal Membrane Oxygenation: a multi-centre study to optimise drug therapy during ECMO. <i>BMC Anesthesiology</i> , 2012, 12, 29.	0.7	90
83	Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014. <i>Internal Medicine Journal</i> , 2014, 44, 1364-1388.	0.5	88
84	The combined effects of extracorporeal membrane oxygenation and renal replacement therapy on meropenem pharmacokinetics: a matched cohort study. <i>Critical Care</i> , 2014, 18, 565.	2.5	87
85	Does contemporary vancomycin dosing achieve therapeutic targets in a heterogeneous clinical cohort of critically ill patients? Data from the multinational DALI study. <i>Critical Care</i> , 2014, 18, R99.	2.5	87
86	Nebulization of Antiinfective Agents in Invasively Mechanically Ventilated Adults. <i>Anesthesiology</i> , 2017, 126, 890-908.	1.3	87
87	Clinical Pharmacokinetics and Pharmacodynamics of Oxazolidinones. <i>Clinical Pharmacokinetics</i> , 2018, 57, 559-575.	1.6	87
88	Improving antibiotic dosing in special situations in the ICU. <i>Current Opinion in Critical Care</i> , 2012, 18, 460-471.	1.6	86
89	Solid nanoparticles for oral antimicrobial drug delivery: a review. <i>Drug Discovery Today</i> , 2019, 24, 858-866.	3.2	86
90	Quantification of seven $\beta$ -lactam antibiotics and two $\beta$ -lactamase inhibitors in human plasma using a validated UPLC-MS/MS method. <i>International Journal of Antimicrobial Agents</i> , 2012, 40, 416-422.	1.1	85

#	ARTICLE	IF	CITATIONS
91	Continuous beta-lactam infusion in critically ill patients: the clinical evidence. <i>Annals of Intensive Care</i> , 2012, 2, 37.	2.2	85
92	Prolonged Infusion Piperacillin-Tazobactam Decreases Mortality and Improves Outcomes in Severely Ill Patients: Results of a Systematic Review and Meta-Analysis*. <i>Critical Care Medicine</i> , 2018, 46, 236-243.	0.4	85
93	The Effect of Renal Replacement Therapy and Antibiotic Dose on Antibiotic Concentrations in Critically Ill Patients: Data From the Multinational Sampling Antibiotics in Renal Replacement Therapy Study. <i>Clinical Infectious Diseases</i> , 2021, 72, 1369-1378.	2.9	85
94	What's behind the failure of emerging antibiotics in the critically ill? Understanding the impact of altered pharmacokinetics and augmented renal clearance. <i>International Journal of Antimicrobial Agents</i> , 2012, 39, 455-457.	1.1	84
95	How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients?. <i>BMC Infectious Diseases</i> , 2014, 14, 288.	1.3	83
96	Vancomycin population pharmacokinetics during extracorporeal membrane oxygenation therapy: a matched cohort study. <i>Critical Care</i> , 2014, 18, 632.	2.5	83
97	Diagnosis and management of invasive candidiasis in the ICU: an updated approach to an old enemy. <i>Critical Care</i> , 2016, 20, 125.	2.5	83
98	Simultaneous determination of seven $\beta$ -lactam antibiotics in human plasma for therapeutic drug monitoring and pharmacokinetic studies. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2014, 960, 134-144.	1.2	82
99	Augmented renal clearance in the Intensive Care Unit: an illustrative case series. <i>International Journal of Antimicrobial Agents</i> , 2010, 35, 606-608.	1.1	81
100	Optimal Doripenem Dosing Simulations in Critically Ill Nosocomial Pneumonia Patients With Obesity, Augmented Renal Clearance, and Decreased Bacterial Susceptibility*. <i>Critical Care Medicine</i> , 2013, 41, 489-495.	0.4	81
101	Antibiotic Dosing in Multiple Organ Dysfunction Syndrome. <i>Chest</i> , 2011, 139, 1210-1220.	0.4	80
102	Association between augmented renal clearance and clinical outcomes in patients receiving $\beta$ -lactam antibiotic therapy by continuous or intermittent infusion: a nested cohort study of the BLING-II randomised, placebo-controlled, clinical trial. <i>International Journal of Antimicrobial Agents</i> , 2017, 49, 624-630.	1.1	80
103	Development of Multiplex PCRs for Detection of Common Viral Pathogens and Agents of Congenital Infections. <i>Journal of Clinical Microbiology</i> , 2005, 43, 5102-5110.	1.8	78
104	Fundamentals of aerosol therapy in critical care. <i>Critical Care</i> , 2016, 20, 269.	2.5	78
105	Pharmacokinetic/pharmacodynamic considerations for the optimization of antimicrobial delivery in the critically ill. <i>Current Opinion in Critical Care</i> , 2015, 21, 412-420.	1.6	75
106	$\beta$ -lactam pharmacokinetics and pharmacodynamics in critically ill patients and strategies for dose optimization: A structured review. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2012, 39, 489-496.	0.9	74
107	Individualization of Piperacillin Dosing for Critically Ill Patients: Dosing Software To Optimize Antimicrobial Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 4094-4102.	1.4	72
108	Pitfalls of using estimations of glomerular filtration rate in an intensive care population. <i>Internal Medicine Journal</i> , 2011, 41, 537-543.	0.5	69

#	ARTICLE	IF	CITATIONS
109	Therapeutic drug monitoring of $\beta$ -lactams for critically ill patients: unwarranted or essential?. <i>International Journal of Antimicrobial Agents</i> , 2010, 35, 419-420.	1.1	68
110	Plasma and Tissue Pharmacokinetics of Cefazolin in Patients Undergoing Elective and Semielective Abdominal Aortic Aneurysm Open Repair Surgery. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 5238-5242.	1.4	68
111	How can we ensure effective antibiotic dosing in critically ill patients receiving different types of renal replacement therapy?. <i>Diagnostic Microbiology and Infectious Disease</i> , 2015, 82, 92-103.	0.8	68
112	Can therapeutic drug monitoring optimize exposure to piperacillin in febrile neutropenic patients with haematological malignancies? A randomized controlled trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2369-2375.	1.3	68
113	Meropenem Dosing in Critically Ill Patients with Sepsis Receiving High-Volume Continuous Venovenous Hemofiltration. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 2974-2978.	1.4	67
114	Can physicochemical properties of antimicrobials be used to predict their pharmacokinetics during extracorporeal membrane oxygenation? Illustrative data from ovine models. <i>Critical Care</i> , 2015, 19, 437.	2.5	67
115	Therapeutic drug monitoring-guided continuous infusion of piperacillin/tazobactam significantly improves pharmacokinetic target attainment in critically ill patients: a retrospective analysis of four years of clinical experience. <i>Infection</i> , 2019, 47, 1001-1011.	2.3	66
116	Using Population Pharmacokinetics To Determine Gentamicin Dosing during Extended Daily Diafiltration in Critically Ill Patients with Acute Kidney Injury. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 3635-3640.	1.4	65
117	Pharmacokinetic evaluation of piperacillin-tazobactam. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2010, 6, 1017-1031.	1.5	65
118	Therapeutic Drug Monitoring of Beta-Lactam Antibiotics in Burns Patients—A One-Year Prospective Study. <i>Therapeutic Drug Monitoring</i> , 2012, 34, 160-164.	1.0	65
119	$\beta$ -Lactam therapeutic drug monitoring in the critically ill: optimising drug exposure in patients with fluctuating renal function and hypoalbuminaemia. <i>International Journal of Antimicrobial Agents</i> , 2013, 41, 162-166.	1.1	65
120	Optimization of dosing regimens and dosing in special populations. <i>Clinical Microbiology and Infection</i> , 2015, 21, 886-893.	2.8	65
121	Determining the mechanisms underlying augmented renal drug clearance in the critically ill: use of exogenous marker compounds. <i>Critical Care</i> , 2014, 18, 657.	2.5	64
122	Plasma and peritoneal fluid population pharmacokinetics of micafungin in post-surgical patients with severe peritonitis. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2854-2861.	1.3	64
123	Impact of 30 mg/kg amikacin and 8 mg/kg gentamicin on serum concentrations in critically ill patients with severe sepsis. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 208-212.	1.3	64
124	Understanding PK/PD. <i>Intensive Care Medicine</i> , 2016, 42, 1797-1800.	3.9	64
125	What is the relevance of fosfomycin pharmacokinetics in the treatment of serious infections in critically ill patients? A systematic review. <i>International Journal of Antimicrobial Agents</i> , 2013, 42, 289-293.	1.1	63
126	Development of a dosing nomogram for continuous-infusion meropenem in critically ill patients based on a validated population pharmacokinetic model. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1330-1339.	1.3	63



#	ARTICLE	IF	CITATIONS
127	How to optimise antimicrobial prescriptions in the Intensive Care Unit: principles of individualised dosing using pharmacokinetics and pharmacodynamics. <i>International Journal of Antimicrobial Agents</i> , 2012, 39, 187-192.	1.1	62
128	Key considerations on nebulization of antimicrobial agents to mechanically ventilated patients. <i>Clinical Microbiology and Infection</i> , 2017, 23, 640-646.	2.8	62
129	Plasma and target-site subcutaneous tissue population pharmacokinetics and dosing simulations of cefazolin in post-trauma critically ill patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1495-1502.	1.3	60
130	Population Pharmacokinetics of Fosfomycin in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 6471-6476.	1.4	59
131	Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible <i>Escherichia coli</i> and <i>Klebsiella spp</i> (the MERINO trial): study protocol for a randomised controlled trial. <i>Trials</i> , 2015, 16, 24.	0.7	57
132	Vancomycin Pharmacokinetics Throughout Life: Results from a Pooled Population Analysis and Evaluation of Current Dosing Recommendations. <i>Clinical Pharmacokinetics</i> , 2019, 58, 767-780.	1.6	57
133	How severe is antibiotic pharmacokinetic variability in critically ill patients and what can be done about it?. <i>Diagnostic Microbiology and Infectious Disease</i> , 2014, 79, 441-447.	0.8	56
134	Vancomycin-associated nephrotoxicity: A meta-analysis of administration by continuous versus intermittent infusion. <i>International Journal of Antimicrobial Agents</i> , 2015, 46, 249-253.	1.1	56
135	Right Dose, Right Now: Customized Drug Dosing in the Critically Ill. <i>Critical Care Medicine</i> , 2017, 45, 331-336.	0.4	55
136	Population Pharmacokinetics of Piperacillin in Nonobese, Obese, and Morbidly Obese Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	54
137	Antimicrobial de-escalation in the critically ill patient and assessment of clinical cure: the DIANA study. <i>Intensive Care Medicine</i> , 2020, 46, 1404-1417.	3.9	54
138	Using PK/PD to Optimize Antibiotic Dosing for Critically Ill Patients. <i>Current Pharmaceutical Biotechnology</i> , 2011, 12, 2070-2079.	0.9	53
139	Characteristics of bloodstream infections in burn patients: An 11-year retrospective study. <i>Burns</i> , 2012, 38, 685-690.	1.1	53
140	Ampicillin/sulbactam: Its potential use in treating infections in critically ill patients. <i>International Journal of Antimicrobial Agents</i> , 2013, 42, 384-389.	1.1	53
141	A new regimen for continuous infusion of vancomycin during continuous renal replacement therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2859-2865.	1.3	52
142	Standard dosing of amikacin and gentamicin in critically ill patients results in variable and subtherapeutic concentrations. <i>International Journal of Antimicrobial Agents</i> , 2015, 46, 21-27.	1.1	52
143	Impact of $\beta$ -lactam antibiotic therapeutic drug monitoring on dose adjustments in critically ill patients undergoing continuous renal replacement therapy. <i>International Journal of Antimicrobial Agents</i> , 2017, 49, 589-594.	1.1	52
144	The need for cost-effectiveness analyses of antimicrobial stewardship programmes: A structured review. <i>International Journal of Antimicrobial Agents</i> , 2015, 46, 140-149.	1.1	51

#	ARTICLE	IF	CITATIONS
145	In vitro removal of anti-infective agents by a novel cytokine adsorbent system. <i>International Journal of Artificial Organs</i> , 2019, 42, 57-64.	0.7	51
146	Diagnostic and medical needs for therapeutic drug monitoring of antibiotics. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2020, 39, 791-797.	1.3	51
147	Towards precision medicine: Therapeutic drug monitoring of guided dosing of vancomycin and $\beta$ -lactam antibiotics to maximize effectiveness and minimize toxicity. <i>American Journal of Health-System Pharmacy</i> , 2020, 77, 1104-1112.	0.5	51
148	The influence of acute kidney injury on antimicrobial dosing in critically ill patients: are dose reductions always necessary?. <i>Diagnostic Microbiology and Infectious Disease</i> , 2014, 79, 77-84.	0.8	50
149	Pharmacokinetics of meropenem in critically ill patients receiving continuous venovenous haemofiltration: A randomised controlled trial of continuous infusion versus intermittent bolus administration. <i>International Journal of Antimicrobial Agents</i> , 2015, 45, 41-45.	1.1	50
150	Enterovirus D68 disease and molecular epidemiology in Australia. <i>Journal of Clinical Virology</i> , 2015, 69, 117-121.	1.6	50
151	Pharmacokinetics and pharmacodynamics in critically ill patients. <i>Current Opinion in Anaesthesiology</i> , 2010, 23, 472-478.	0.9	49
152	Augmented Renal Clearance in Traumatic Brain Injury: A Single-Center Observational Study of Atrial Natriuretic Peptide, Cardiac Output, and Creatinine Clearance. <i>Journal of Neurotrauma</i> , 2017, 34, 137-144.	1.7	49
153	$\beta$ -Lactam Dosage Regimens in Septic Patients with Augmented Renal Clearance. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	49
154	Population Pharmacokinetics of Fluconazole in Critically Ill Patients Receiving Continuous Venovenous Hemodiafiltration: Using Monte Carlo Simulations To Predict Doses for Specified Pharmacodynamic Targets. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 5868-5873.	1.4	48
155	Population pharmacokinetics and dosing simulations of amoxicillin/clavulanic acid in critically ill patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2600-2608.	1.3	48
156	Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: Lessons from the DALI Study. <i>International Journal of Antimicrobial Agents</i> , 2014, 43, 423-430.	1.1	48
157	Individualising Therapy to Minimize Bacterial Multidrug Resistance. <i>Drugs</i> , 2018, 78, 621-641.	4.9	48
158	DALI: Defining Antibiotic Levels in Intensive care unit patients: a multi-centre point of prevalence study to determine whether contemporary antibiotic dosing for critically ill patients is therapeutic. <i>BMC Infectious Diseases</i> , 2012, 12, 152.	1.3	47
159	Improving vancomycin prescription in critical illness through a drug use evaluation process: a weight-based dosing intervention study. <i>International Journal of Antimicrobial Agents</i> , 2012, 39, 69-72.	1.1	47
160	Decreasing the time to achieve therapeutic vancomycin concentrations in critically ill patients: developing and testing of a dosing nomogram. <i>Critical Care</i> , 2014, 18, 654.	2.5	47
161	Plasma and cerebrospinal fluid concentrations of linezolid in neurosurgical critically ill patients with proven or suspected central nervous system infections. <i>International Journal of Antimicrobial Agents</i> , 2014, 44, 409-415.	1.1	47
162	The Global Alliance for Infections in Surgery: defining a model for antimicrobial stewardship—results from an international cross-sectional survey. <i>World Journal of Emergency Surgery</i> , 2017, 12, 34.	2.1	47

#	ARTICLE	IF	CITATIONS
163	Impact of Quality Bundle Enforcement by a Critical Care Pharmacist on Patient Outcome and Costs*. <i>Critical Care Medicine</i> , 2018, 46, 199-207.	0.4	47
164	Global survey on nebulization of antimicrobial agents in mechanically ventilated patients: a call for international guidelines. <i>Clinical Microbiology and Infection</i> , 2016, 22, 359-364.	2.8	46
165	The effects of major burn related pathophysiological changes on the pharmacokinetics and pharmacodynamics of drug use: An appraisal utilizing antibiotics. <i>Advanced Drug Delivery Reviews</i> , 2018, 123, 65-74.	6.6	46
166	Using pharmacokinetics and pharmacodynamics to optimise dosing of antifungal agents in critically ill patients: a systematic review. <i>International Journal of Antimicrobial Agents</i> , 2012, 39, 1-10.	1.1	45
167	Pharmacokinetics of piperacillin and tazobactam in plasma and subcutaneous interstitial fluid in critically ill patients receiving continuous venovenous haemodiafiltration. <i>International Journal of Antimicrobial Agents</i> , 2014, 43, 343-348.	1.1	45
168	Quantitative bioanalytical validation of fosfomycin in human whole blood with volumetric absorptive microsampling. <i>Bioanalysis</i> , 2015, 7, 2585-2595.	0.6	45
169	New Regimen for Continuous Infusion of Vancomycin in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 4750-4756.	1.4	45
170	Intrapulmonary pharmacokinetics of antibiotics used to treat nosocomial pneumonia caused by Gram-negative bacilli: A systematic review. <i>International Journal of Antimicrobial Agents</i> , 2019, 53, 234-245.	1.1	45
171	Antibiotic dosing during extracorporeal membrane oxygenation: does the system matter?. <i>Current Opinion in Anaesthesiology</i> , 2020, 33, 71-82.	0.9	45
172	Can population pharmacokinetic modelling guide vancomycin dosing during continuous renal replacement therapy in critically ill patients?. <i>International Journal of Antimicrobial Agents</i> , 2013, 41, 564-568.	1.1	44
173	The efficacy and safety of adrenergic blockade after burn injury. <i>Journal of Trauma and Acute Care Surgery</i> , 2016, 80, 146-155.	1.1	44
174	Antibiotic dosing in the 'at risk' critically ill patient: Linking pathophysiology with pharmacokinetics/pharmacodynamics in sepsis and trauma patients. <i>BMC Anesthesiology</i> , 2011, 11, 3.	0.7	43
175	Population pharmacokinetics/pharmacodynamics of micafungin against <i>Candida</i> species in obese, critically ill, and morbidly obese critically ill patients. <i>Critical Care</i> , 2018, 22, 94.	2.5	43
176	Population pharmacokinetics and evaluation of the predictive performance of pharmacokinetic models in critically ill patients receiving continuous infusion meropenem: a comparison of eight pharmacokinetic models. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 432-441.	1.3	43
177	Altered antibiotic pharmacokinetics during extracorporeal membrane oxygenation: cause for concern?. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 726-727.	1.3	42
178	Population Pharmacokinetics of Tigecycline in Critically Ill Patients with Severe Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	42
179	Pharmacodynamic Target Attainment for Cefepime, Meropenem, and Piperacillin-Tazobactam Using a Pharmacokinetic/Pharmacodynamic-Based Dosing Calculator in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	42
180	Infrared Based Saliva Screening Test for COVID-19. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 17102-17107.	7.2	42

#	ARTICLE	IF	CITATIONS
181	Optimizing dosing of antibiotics in critically ill patients. <i>Current Opinion in Infectious Diseases</i> , 2015, 28, 497-504.	1.3	41
182	Risk Factors in Hospitalized Patients With Burn Injuries for Developing Heterotopic Ossification – A Retrospective Analysis. <i>Journal of Burn Care and Research</i> , 2015, 36, 465-470.	0.2	41
183	Model-Informed Drug Development for Anti-Infectives: State of the Art and Future. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 867-891.	2.3	41
184	Prolonged administration of $\beta$ -lactam antibiotics – a comprehensive review and critical appraisal. <i>Swiss Medical Weekly</i> , 2016, 146, w14368.	0.8	41
185	LC-MS/MS for Therapeutic Drug Monitoring of anti-infective drugs. <i>TrAC - Trends in Analytical Chemistry</i> , 2016, 84, 34-40.	5.8	40
186	Maximally effective dosing regimens of meropenem in patients with septic shock. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 191-198.	1.3	40
187	Antibiotic dose optimization in critically ill patients. <i>Medicina Intensiva</i> , 2015, 39, 563-572.	0.4	39
188	Intratracheal Administration of Antimicrobial Agents in Mechanically Ventilated Adults: An International Survey on Delivery Practices and Safety. <i>Respiratory Care</i> , 2016, 61, 1008-1014.	0.8	39
189	BK viral infection in an Australian pediatric renal transplant population. <i>Pediatric Transplantation</i> , 2004, 8, 480-484.	0.5	38
190	Antimicrobial chemotherapy and lung microdialysis: a review. <i>International Journal of Antimicrobial Agents</i> , 2010, 36, 491-500.	1.1	38
191	The ECMO PK Project: an incremental research approach to advance understanding of the pharmacokinetic alterations and improve patient outcomes during extracorporeal membrane oxygenation. <i>BMC Anesthesiology</i> , 2013, 13, 7.	0.7	38
192	Antibacterial therapeutic drug monitoring in cerebrospinal fluid: difficulty in achieving adequate drug concentrations. <i>Journal of Neurosurgery</i> , 2013, 118, 297-301.	0.9	38
193	Effect of Obesity on the Population Pharmacokinetics of Meropenem in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 4577-4584.	1.4	38
194	Effect of Obesity on the Population Pharmacokinetics of Fluconazole in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6550-6557.	1.4	38
195	Effect of different renal function on antibacterial effects of piperacillin against <i>Pseudomonas aeruginosa</i> evaluated via the hollow-fibre infection model and mechanism-based modelling. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2509-2520.	1.3	38
196	Population pharmacokinetics of continuous infusion of piperacillin in critically ill patients. <i>International Journal of Antimicrobial Agents</i> , 2018, 51, 594-600.	1.1	38
197	Altered Pharmacokinetics of Piperacillin in Febrile Neutropenic Patients with Hematological Malignancy. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3533-3537.	1.4	37
198	What is the effect of obesity on piperacillin and meropenem trough concentrations in critically ill patients?. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 696-702.	1.3	37

#	ARTICLE	IF	CITATIONS
199	Imported Case of Poliomyelitis, Melbourne, Australia, 2007. <i>Emerging Infectious Diseases</i> , 2009, 15, 63-65.	2.0	36
200	Subtleties in practical application of prolonged infusion of $\beta$ -lactam antibiotics. <i>International Journal of Antimicrobial Agents</i> , 2015, 45, 461-463.	1.1	36
201	Interethnic Differences in Pharmacokinetics of Antibacterials. <i>Clinical Pharmacokinetics</i> , 2015, 54, 243-260.	1.6	36
202	Population pharmacokinetics of linezolid in critically ill patients on renal replacement therapy: comparison of equal doses in continuous venovenous haemofiltration and continuous venovenous haemodiafiltration. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 464-470.	1.3	36
203	Pharmacokinetics/Pharmacodynamics of $\beta$ -Lactams and Therapeutic Drug Monitoring: From Theory to Practical Issues in the Intensive Care Unit. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2019, 40, 476-487.	0.8	36
204	Antibiotic exposure at the site of infection: principles and assessment of tissue penetration. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 623-634.	1.3	36
205	Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2021. <i>Internal Medicine Journal</i> , 2021, 51, 67-88.	0.5	36
206	Micafungin pharmacokinetic/pharmacodynamic adequacy for the treatment of invasive candidiasis in critically ill patients on continuous venovenous haemofiltration. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1624-1632.	1.3	35
207	Population Pharmacokinetics of Unbound Ceftolozane and Tazobactam in Critically Ill Patients without Renal Dysfunction. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	35
208	$\beta$ -Lactam pharmacodynamics in Gram-negative bloodstream infections in the critically ill. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 429-433.	1.3	35
209	Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	34
210	Population pharmacokinetics of total and unbound teicoplanin concentrations and dosing simulations in patients with haematological malignancy. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 995-1003.	1.3	34
211	What Are the Current Approaches to Optimising Antimicrobial Dosing in the Intensive Care Unit?. <i>Pharmaceutics</i> , 2020, 12, 638.	2.0	33
212	Antimicrobial Stewardship in Australian Hospitals and Other Settings. <i>Infectious Diseases and Therapy</i> , 2015, 4, 27-38.	1.8	32
213	Caspofungin Population Pharmacokinetics in Critically Ill Patients Undergoing Continuous Veno-Venous Haemofiltration or Haemodiafiltration. <i>Clinical Pharmacokinetics</i> , 2017, 56, 1057-1068.	1.6	32
214	Uncertainty in Antibiotic Dosing in Critically Ill Neonate and Pediatric Patients: Can Microsampling Provide the Answers?. <i>Clinical Therapeutics</i> , 2016, 38, 1961-1975.	1.1	31
215	A Global Declaration on Appropriate Use of Antimicrobial Agents across the Surgical Pathway. <i>Surgical Infections</i> , 2017, 18, 846-853.	0.7	31
216	Therapeutic drug monitoring-based dose optimisation of piperacillin/tazobactam to improve outcome in patients with sepsis (TARGET): a prospective, multi-centre, randomised controlled trial. <i>Trials</i> , 2019, 20, 330.	0.7	31

#	ARTICLE	IF	CITATIONS
217	How to design a study to evaluate therapeutic drug monitoring in infectious diseases?. <i>Clinical Microbiology and Infection</i> , 2020, 26, 1008-1016.	2.8	31
218	Therapeutic Drug Monitoring of Antibiotics: Defining the Therapeutic Range. <i>Therapeutic Drug Monitoring</i> , 2022, 44, 19-31.	1.0	31
219	Population pharmacokinetics and dosing simulations of cefuroxime in critically ill patients: non-standard dosing approaches are required to achieve therapeutic exposures. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2797-2803.	1.3	30
220	Antimicrobial stewardship activities: a survey of Queensland hospitals. <i>Australian Health Review</i> , 2014, 38, 557.	0.5	30
221	Optimising meropenem dosing in critically ill Australian Indigenous patients with severe sepsis. <i>International Journal of Antimicrobial Agents</i> , 2016, 48, 542-546.	1.1	30
222	Fosfomycin efficacy and emergence of resistance among Enterobacteriaceae in an in vitro dynamic bladder infection model. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 709-719.	1.3	30
223	Cefepime versus ceftazidime: considerations for empirical use in critically ill patients. <i>International Journal of Antimicrobial Agents</i> , 2007, 29, 117-128.	1.1	29
224	Doripenem population pharmacokinetics and dosing requirements for critically ill patients receiving continuous venovenous haemodiafiltration. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2508-2516.	1.3	29
225	Effect of time on recovery of plasma microsamples for the quantitative determination of vancomycin. <i>Bioanalysis</i> , 2016, 8, 2235-2242.	0.6	29
226	Influence of Renal Replacement Modalities on Amikacin Population Pharmacokinetics in Critically Ill Patients on Continuous Renal Replacement Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 4901-4909.	1.4	29
227	Population pharmacokinetics of teicoplanin and attainment of pharmacokinetic/pharmacodynamic targets in adult patients with haematological malignancy. <i>Clinical Microbiology and Infection</i> , 2017, 23, 674.e7-674.e13.	2.8	29
228	Pharmacokinetics of piperacillin in critically ill patients receiving continuous venovenous haemofiltration: A randomised controlled trial of continuous infusion versus intermittent bolus administration. <i>International Journal of Antimicrobial Agents</i> , 2015, 46, 39-44.	1.1	28
229	A simple LC-MS/MS method using HILIC chromatography for the determination of fosfomycin in plasma and urine: Application to a pilot pharmacokinetic study in humans. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015, 105, 39-45.	1.4	28
230	Pharmacokinetics of meropenem in septic patients on sustained low-efficiency dialysis: a population pharmacokinetic study. <i>Critical Care</i> , 2018, 22, 25.	2.5	28
231	Pharmacokinetics/Pharmacodynamics of Antiviral Agents Used to Treat SARS-CoV-2 and Their Potential Interaction with Drugs and Other Supportive Measures: A Comprehensive Review by the PK/PD of Anti-Infectives Study Group of the European Society of Antimicrobial Agents. <i>Clinical Pharmacokinetics</i> , 2020, 59, 1195-1216.	1.6	28
232	Pharmacokinetics of Beta-Lactam Antibiotics in Patients with Intra-Abdominal Disease: A Structured Review. <i>Surgical Infections</i> , 2012, 13, 9-17.	0.7	27
233	Population pharmacokinetics and dose simulation of vancomycin in critically ill patients during high-volume haemofiltration. <i>International Journal of Antimicrobial Agents</i> , 2014, 44, 163-167.	1.1	27
234	Anti-Infective Drugs during Continuous Hemodialysis – Using the Bench to Learn What to do at the Bedside. <i>International Journal of Artificial Organs</i> , 2015, 38, 17-22.	0.7	27

#	ARTICLE	IF	CITATIONS
235	<i>Ex Vivo</i> Characterization of Effects of Renal Replacement Therapy Modalities and Settings on Pharmacokinetics of Meropenem and Vaborbactam. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	27
236	The <i>Staphylococcus aureus</i> Network Adaptive Platform Trial Protocol: New Tools for an Old Foe. <i>Clinical Infectious Diseases</i> , 2022, 75, 2027-2034.	2.9	27
237	Comparison of the Accuracy and Precision of Pharmacokinetic Equations To Predict Free Meropenem Concentrations in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1411-1417.	1.4	26
238	Difference in maxillary sinus volumes of patients with cleft lip and palate. <i>International Journal of Pediatric Otorhinolaryngology</i> , 2014, 78, 2234-2236.	0.4	25
239	The use and risks of antibiotics in critically ill patients. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 667-678.	1.0	25
240	Dosing antibiotic prophylaxis during cardiopulmonary bypass—a higher level of complexity? A structured review. <i>International Journal of Antimicrobial Agents</i> , 2017, 49, 395-402.	1.1	25
241	Comparative total and unbound pharmacokinetics of cefazolin administered by bolus versus continuous infusion in patients undergoing major surgery: a randomized controlled trial. <i>British Journal of Anaesthesia</i> , 2017, 118, 876-882.	1.5	25
242	Does Furosemide Increase Oxidative Stress in Acute Kidney Injury?. <i>Antioxidants and Redox Signaling</i> , 2017, 26, 221-226.	2.5	25
243	Clinical application of microsampling versus conventional sampling techniques in the quantitative bioanalysis of antibiotics: a systematic review. <i>Bioanalysis</i> , 2018, 10, 407-423.	0.6	25
244	Population pharmacokinetics of vancomycin in critically ill patients receiving prolonged intermittent renal replacement therapy. <i>International Journal of Antimicrobial Agents</i> , 2018, 52, 151-157.	1.1	25
245	Early target attainment of continuous infusion piperacillin/tazobactam and meropenem in critically ill patients: A prospective observational study. <i>Journal of Critical Care</i> , 2019, 52, 75-79.	1.0	25
246	Personalized antibiotic dosing for the critically ill. <i>Intensive Care Medicine</i> , 2019, 45, 715-718.	3.9	25
247	Is high-dose $\beta$ -lactam therapy associated with excessive drug toxicity in critically ill patients?. <i>Minerva Anestesiologica</i> , 2016, 82, 957-65.	0.6	25
248	Characterization of Poliovirus Variants Selected for Resistance to the Antiviral Compound V-073. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5568-5574.	1.4	24
249	Pharmacokinetics of meropenem and piperacillin in critically ill patients with indwelling surgical drains. <i>International Journal of Antimicrobial Agents</i> , 2013, 42, 90-93.	1.1	24
250	The Effect of Paracetamol on Core Body Temperature in Acute Traumatic Brain Injury: A Randomised, Controlled Clinical Trial. <i>PLoS ONE</i> , 2015, 10, e0144740.	1.1	24
251	Comparative Population Plasma and Tissue Pharmacokinetics of Micafungin in Critically Ill Patients with Severe Burn Injuries and Patients with Complicated Intra-Abdominal Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 5914-5921.	1.4	24
252	Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy and haemopoietic stem cell transplant recipients, 2021. <i>Internal Medicine Journal</i> , 2021, 51, 37-66.	0.5	24

#	ARTICLE	IF	CITATIONS
253	Pharmacodynamic profiling of intravenous antibiotics against prevalent Gram-negative organisms across the globe: the PASSPORT Programâ€”Asia-Pacific Region. <i>International Journal of Antimicrobial Agents</i> , 2011, 37, 225-229.	1.1	23
254	A validated method for the quantification of fosfomycin on dried plasma spots by HPLCâ€”MS/MS: Application to a pilot pharmacokinetic study in humans. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015, 115, 509-514.	1.4	23
255	Population pharmacokinetics and dosing simulations of cefepime in septic shock patients receiving continuous renal replacement therapy. <i>International Journal of Antimicrobial Agents</i> , 2015, 46, 413-419.	1.1	23
256	Adequacy of High-Dose Cefepime Regimen in Febrile Neutropenic Patients with Hematological Malignancies. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 5463-5469.	1.4	23
257	A UHPLCâ€”MS/MS method for the simultaneous determination of piperacillin and tazobactam in plasma (total and unbound), urine and renal replacement therapy effluent. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 148, 324-333.	1.4	23
258	Microfluidic assembly of pomegranate-like hierarchical microspheres for efflux regulation in oral drug delivery. <i>Acta Biomaterialia</i> , 2021, 126, 277-290.	4.1	23
259	Emerging therapeutic drug monitoring of antiâ€”infective agents in Australian hospitals: Availability, performance and barriers to implementation. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 669-679.	1.1	23
260	Determinants of Urinary Output Response to IV Furosemide in Acute Kidney Injury: A Pharmacokinetic/Pharmacodynamic Study. <i>Critical Care Medicine</i> , 2016, 44, e923-e929.	0.4	22
261	Total and unbound ceftriaxone pharmacokinetics in critically ill Australian Indigenous patients with severe sepsis. <i>International Journal of Antimicrobial Agents</i> , 2016, 48, 748-752.	1.1	22
262	Determination of Cefalothin and Cefazolin in Human Plasma, Urine and Peritoneal Dialysate by UHPLCâ€”MS/MS: application to a pilot pharmacokinetic study in humans. <i>Biomedical Chromatography</i> , 2016, 30, 872-879.	0.8	22
263	Using Population Pharmacokinetic Modeling and Monte Carlo Simulations To Determine whether Standard Doses of Piperacillin in Piperacillin-Tazobactam Regimens Are Adequate for the Management of Febrile Neutropenia. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	22
264	Pharmacodynamics of Aerosolized Fosfomycin and Amikacin against Resistant Clinical Isolates of <i>Pseudomonas aeruginosa</i> and <i>Klebsiella pneumoniae</i> in a Hollow-Fiber Infection Model: Experimental Basis for Combination Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	22
265	Antibiotic Distribution into Cerebrospinal Fluid: Can Dosing Safely Account for Drug and Disease Factors in the Treatment of Ventriculostomy-Associated Infections?. <i>Clinical Pharmacokinetics</i> , 2018, 57, 439-454.	1.6	22
266	How to optimize antibiotic pharmacokinetic/pharmacodynamics for Gram-negative infections in critically ill patients. <i>Current Opinion in Infectious Diseases</i> , 2018, 31, 555-565.	1.3	22
267	Population pharmacokinetics of total and unbound concentrations of intravenous posaconazole in adult critically ill patients. <i>Critical Care</i> , 2019, 23, 205.	2.5	22
268	Oral meropenem for superbugs: challenges and opportunities. <i>Drug Discovery Today</i> , 2021, 26, 551-560.	3.2	22
269	Liquid CO <sub>2</sub> Formulated Mesoporous Silica Nanoparticles for pH-Responsive Oral Delivery of Meropenem. <i>ACS Biomaterials Science and Engineering</i> , 2021, 7, 1836-1853.	2.6	22
270	Are interstitial fluid concentrations of meropenem equivalent to plasma concentrations in critically ill patients receiving continuous renal replacement therapy?. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 528-533.	1.3	21



#	ARTICLE	IF	CITATIONS
271	Impact of the MIC of piperacillin/tazobactam on the outcome for patients with bacteraemia due to Enterobacteriaceae: the Bacteraemia-MIC project. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 521-530.	1.3	21
272	Variability in Trough Total and Unbound Teicoplanin Concentrations and Achievement of Therapeutic Drug Monitoring Targets in Adult Patients with Hematological Malignancy. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	21
273	Optimization and Evaluation of Piperacillin-Tobramycin Combination Dosage Regimens against <i>Pseudomonas aeruginosa</i> for Patients with Altered Pharmacokinetics via the Hollow-Fiber Infection Model and Mechanism-Based Modeling. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	21
274	Meropenem-Tobramycin Combination Regimens Combat Carbapenem-Resistant <i>Pseudomonas aeruginosa</i> in the Hollow-Fiber Infection Model Simulating Augmented Renal Clearance in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 64, .	1.4	21
275	A Population Pharmacokinetic Model-Guided Evaluation of Ceftolozane-Tazobactam Dosing in Critically Ill Patients Undergoing Continuous Venovenous Hemodiafiltration. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 64, .	1.4	21
276	$\hat{I}^2$ -lactam antibiotic versus combined $\hat{I}^2$ -lactam antibiotics and single daily dosing regimens of aminoglycosides for treating serious infections: A meta-analysis. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105839.	1.1	21
277	A personalised approach to antibiotic pharmacokinetics and pharmacodynamics in critically ill patients. <i>Anaesthesia, Critical Care &amp; Pain Medicine</i> , 2021, 40, 100970.	0.6	21
278	Consensus guidelines for the diagnosis and management of invasive candidiasis in haematology, oncology and intensive care settings, 2021. <i>Internal Medicine Journal</i> , 2021, 51, 89-117.	0.5	21
279	Sustained low efficiency dialysis allows rational renal replacement therapy, but does it allow rational drug dosing?*. <i>Critical Care Medicine</i> , 2011, 39, 602-603.	0.4	20
280	Infusional $\hat{I}^2$ -lactam antibiotics in febrile neutropenia. <i>Current Opinion in Infectious Diseases</i> , 2012, 25, 619-625.	1.3	20
281	Editorial Commentary: Closing the Loop—A Colistin Clinical Study to Confirm Dosing Recommendations From PK/PD Modeling. <i>Clinical Infectious Diseases</i> , 2012, 54, 1727-1729.	2.9	20
282	Low Flucloxacillin Concentrations in a Patient With Central Nervous System Infection. <i>Annals of Pharmacotherapy</i> , 2014, 48, 1380-1384.	0.9	20
283	Streamlined research funding using short proposals and accelerated peer review: an observational study. <i>BMC Health Services Research</i> , 2015, 15, 55.	0.9	20
284	Albumin concentration significantly impacts on free teicoplanin plasma concentrations in non-critically ill patients with chronic bone sepsis. <i>International Journal of Antimicrobial Agents</i> , 2015, 45, 647-651.	1.1	20
285	Is there a role for microsampling in antibiotic pharmacokinetic studies?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 601-614.	1.5	20
286	Comparative Evaluation of the Predictive Performances of Three Different Structural Population Pharmacokinetic Models To Predict Future Voriconazole Concentrations. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6806-6812.	1.4	20
287	Population pharmacokinetics and dosing simulations of ceftazidime in critically ill patients receiving sustained low-efficiency dialysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 1433-1440.	1.3	20
288	Impact of renal replacement modalities on the clearance of piperacillin-tazobactam administered via continuous infusion in critically ill patients. <i>International Journal of Antimicrobial Agents</i> , 2017, 50, 227-231.	1.1	20

#	ARTICLE	IF	CITATIONS
289	Multidrug-resistant <i>Acinetobacter baumannii</i> infections: Current evidence on treatment options and the role of pharmacokinetics/pharmacodynamics in dose optimisation. <i>International Journal of Antimicrobial Agents</i> , 2019, 53, 726-745.	1.1	20
290	Antimicrobial dosing in critical care: A pragmatic adult dosing nomogram. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105837.	1.1	20
291	Nebulized Colistin in Ventilator-Associated Pneumonia and Tracheobronchitis: Historical Background, Pharmacokinetics and Perspectives. <i>Microorganisms</i> , 2021, 9, 1154.	1.6	20
292	Evaluation of Medication-Related Problems in Medication Reviews: A Comparative Perspective. <i>Annals of Pharmacotherapy</i> , 2012, 46, 972-982.	0.9	19
293	A Simulation Study Reveals Lack of Pharmacokinetic/Pharmacodynamic Target Attainment in De-escalated Antibiotic Therapy in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 4689-4694.	1.4	19
294	Is inhaled prophylactic heparin useful for prevention and Management of Pneumonia in ventilated ICU patients?. <i>Journal of Critical Care</i> , 2016, 34, 95-102.	1.0	19
295	Pharmacokinetics of a novel dosing regimen of oral melatonin in critically ill patients. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, 467-72.	1.4	19
296	Oral Fosfomycin Treatment for Enterococcal Urinary Tract Infections in a Dynamic <i>In Vitro</i> Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	19
297	Development of simulated and ovine models of extracorporeal life support to improve understanding of circuit-host interactions. <i>Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine</i> , 2012, 14, 105-11.	0.0	19
298	Pharmacokinetics of Intraperitoneal Gentamicin in Peritoneal Dialysis Patients with Peritonitis (GIPD) Tj ETQq0 0 0 r gBT /Overlock 10 Tf	2.2	18
299	Investigation of a predicted N-terminal amphipathic $\alpha$ -helix using atomistic molecular dynamics simulation of a complete prototype poliovirus virion. <i>Journal of Molecular Graphics and Modelling</i> , 2012, 38, 165-173.	1.3	18
300	Defining Antibiotic Dosing in Lung Infections. <i>Clinical Pulmonary Medicine</i> , 2013, 20, 121-128.	0.3	18
301	Should $\beta$ -lactam antibiotics be administered by continuous infusion in critically ill patients? A survey of Australia and New Zealand intensive care unit doctors and pharmacists. <i>International Journal of Antimicrobial Agents</i> , 2016, 47, 436-438.	1.1	18
302	<i>In Vivo</i> Microdialysis To Determine Subcutaneous Interstitial Fluid Penetration and Pharmacokinetics of Fluconazole in Intensive Care Unit Patients with Sepsis. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 827-832.	1.4	18
303	Defining optimal dosing of ciprofloxacin in patients with septic shock. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1662-1669.	1.3	18
304	Overcoming barriers to optimal drug dosing during ECMO in critically ill adult patients. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 103-112.	1.5	18
305	Prolonged Versus Intermittent Infusion of $\beta$ -Lactam Antibiotics: A Systematic Review and Meta-Regression of Bacterial Killing in Preclinical Infection Models. <i>Clinical Pharmacokinetics</i> , 2020, 59, 1237-1250.	1.6	18
306	Finding the relevance of antimicrobial stewardship for cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2020, 19, 511-520.	0.3	18

#	ARTICLE	IF	CITATIONS
307	Optimization of flucloxacillin dosing regimens in critically ill patients using population pharmacokinetic modelling of total and unbound concentrations. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2641-2649.	1.3	18
308	Optimizing Use of $\beta$ -Lactam Antibiotics in the Critically Ill. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2007, 28, 579-585.	0.8	17
309	Does Critical Illness Change Levofloxacin Pharmacokinetics?. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 1459-1463.	1.4	17
310	An LC-MS/MS method to determine vancomycin in plasma (total and unbound), urine and renal replacement therapy effluent. <i>Bioanalysis</i> , 2017, 9, 911-924.	0.6	17
311	Identifying at-risk-patients for sub-optimal beta-lactam exposure in critically ill patients with severe infections. <i>Critical Care</i> , 2017, 21, 283.	2.5	17
312	Pharmacokinetics of Intravenous Posaconazole in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	17
313	Intravenous fosfomycin for the treatment of multidrug-resistant pathogens: what is the evidence on dosing regimens?. <i>Expert Review of Anti-Infective Therapy</i> , 2019, 17, 201-210.	2.0	17
314	Vancomycin population pharmacokinetics for adult patients with sepsis or septic shock: are current dosing regimens sufficient?. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 1219-1226.	0.8	17
315	Linezolid Dosing in Patients With Liver Cirrhosis: Standard Dosing Risk Toxicity. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 732-739.	1.0	17
316	Lung Pharmacokinetics of Tobramycin by Intravenous and Nebulized Dosing in a Mechanically Ventilated Healthy Ovine Model. <i>Anesthesiology</i> , 2019, 131, 344-355.	1.3	17
317	Therapeutic drug monitoring of commonly used anti-infective agents: A nationwide cross-sectional survey of Australian hospital practices. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106180.	1.1	17
318	PLGA encapsulated $\beta$ -cyclodextrin-meropenem inclusion complex formulation for oral delivery. <i>International Journal of Pharmaceutics</i> , 2021, 597, 120280.	2.6	17
319	Antibiotic dosing in critically ill patients with septic shock and on continuous renal replacement therapy: can we resolve this problem with pharmacokinetic studies and dosing guidelines?. <i>Critical Care</i> , 2014, 18, 156.	2.5	16
320	Cefazolin plasma protein binding in different human populations: More than cefazolin-albumin interaction. <i>International Journal of Antimicrobial Agents</i> , 2014, 43, 199-200.	1.1	16
321	Pharmacokinetics and preliminary safety of high dose linezolid for the treatment of Gram-positive bacterial infections. <i>Journal of Infection</i> , 2015, 71, 604-607.	1.7	16
322	Comparison of equal doses of continuous venovenous haemofiltration and haemodiafiltration on ciprofloxacin population pharmacokinetics in critically ill patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1643-1650.	1.3	16
323	Pharmacokinetics of piperacillin in critically ill patients with acute kidney injury receiving sustained low-efficiency diafiltration. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1647-1650.	1.3	16
324	Amikacin Initial Dose in Critically Ill Patients: a Nonparametric Approach To Optimize <i>A Priori</i> Pharmacokinetic/Pharmacodynamic Target Attainments in Individual Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	16

#	ARTICLE	IF	CITATIONS
325	Prolonged infusion of beta-lactam antibiotics for Gram-negative infections: rationale and evidence base. <i>Current Opinion in Infectious Diseases</i> , 2020, 33, 501-510.	1.3	16
326	Pharmacokinetic/pharmacodynamic adequacy of polymyxin B against extensively drug-resistant Gram-negative bacteria in critically ill, general ward and cystic fibrosis patient populations. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105943.	1.1	16
327	Population Pharmacokinetics of Levetiracetam in Patients with Traumatic Brain Injury and Subarachnoid Hemorrhage Exhibiting Augmented Renal Clearance. <i>Clinical Pharmacokinetics</i> , 2021, 60, 655-664.	1.6	16
328	Evaluation of Meropenem+Ciprofloxacin Combination Dosage Regimens for the Pharmacokinetics of Critically Ill Patients With Augmented Renal Clearance. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1104-1115.	2.3	16
329	Continuous infusion of $\beta$ -lactams in the intensive care unit"Best way to hit the target?*. <i>Critical Care Medicine</i> , 2008, 36, 1663-1664.	0.4	15
330	The Use of Bloodstream Infection Mortality to Measure the Impact of Antimicrobial Stewardship Interventions: Assessing the Evidence. <i>Gastroenterology Insights</i> , 2017, 9, 6849.	0.7	15
331	Cerebrospinal Fluid Penetration of Ceftolozane-Tazobactam in Critically Ill Patients with an Indwelling External Ventricular Drain. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 65, .	1.4	15
332	Ceftolozane+tazobactam in an elastomeric infusion device for ambulatory care: an in vitro stability study. <i>European Journal of Hospital Pharmacy</i> , 2020, 27, e84-e86.	0.5	15
333	An international survey on aminoglycoside practices in critically ill patients: the AMINO III study. <i>Annals of Intensive Care</i> , 2021, 11, 49.	2.2	15
334	Infrared Based Saliva Screening Test for COVID-19. <i>Angewandte Chemie</i> , 2021, 133, 17239-17244.	1.6	15
335	Lessons learnt in the pharmacokinetic analysis of the effect of haemoperfusion for acute overdose with sustained-release diltiazem. <i>Anaesthesia</i> , 2008, 63, 714-718.	1.8	14
336	Pharmacokinetics of Piperacillin in Critically Ill Australian Indigenous Patients with Severe Sepsis. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 7402-7406.	1.4	14
337	Sampling Antibiotics in Renal Replacement Therapy (SMARRT): an observational pharmacokinetic study in critically ill patients. <i>BMC Infectious Diseases</i> , 2016, 16, 103.	1.3	14
338	Understanding the impact of pathophysiological alterations during critical illness on drug pharmacokinetics. <i>Anaesthesia, Critical Care &amp; Pain Medicine</i> , 2018, 37, 515-517.	0.6	14
339	Piperacillin Population Pharmacokinetics in Critically Ill Adults During Sustained Low-Efficiency Dialysis. <i>Annals of Pharmacotherapy</i> , 2018, 52, 965-973.	0.9	14
340	Saturable elimination of piperacillin in critically ill patients: implications for continuous infusion. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 741-749.	1.1	14
341	Augmented renal clearance: A real phenomenon with an uncertain cause. <i>Anaesthesia, Critical Care &amp; Pain Medicine</i> , 2019, 38, 335-336.	0.6	14
342	Plasma and interstitial fluid population pharmacokinetics of vancomycin in critically ill patients with sepsis. <i>International Journal of Antimicrobial Agents</i> , 2019, 53, 137-142.	1.1	14

#	ARTICLE	IF	CITATIONS
343	Conventional Pig as Animal Model for Human Renal Drug Excretion Processes: Unravelling the Porcine Renal Function by Use of a Cocktail of Exogenous Markers. <i>Frontiers in Pharmacology</i> , 2020, 11, 883.	1.6	14
344	Prophylactic Cefazolin Dosing in Women With Body Mass Index $\geq 35 \text{ kg}\cdot\text{m}^{-2}$ Undergoing Cesarean Delivery: A Pharmacokinetic Study of Plasma and Interstitial Fluid. <i>Anesthesia and Analgesia</i> , 2020, 131, 199-207.	1.1	14
345	Population Pharmacokinetics and Dosing Recommendations of Levetiracetam in Adult and Elderly Patients With Epilepsy. <i>Journal of Pharmaceutical Sciences</i> , 2020, 109, 2070-2078.	1.6	14
346	Personalized Piperacillin Dosing for the Critically Ill: A Retrospective Analysis of Clinical Experience with Dosing Software and Therapeutic Drug Monitoring to Optimize Antimicrobial Dosing. <i>Antibiotics</i> , 2021, 10, 667.	1.5	14
347	Therapeutic drug monitoring when using cefepime in continuous renal replacement therapy: seizures associated with cefepime. <i>Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine</i> , 2012, 14, 312-5.	0.0	14
348	A novel way to investigate the effects of plasma exchange on antibiotic levels: use of microdialysis. <i>International Journal of Antimicrobial Agents</i> , 2008, 31, 240-244.	1.1	13
349	Pharmacokinetic evaluation of fluconazole in critically ill patients. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 1431-1440.	1.5	13
350	Can We Use an Ex Vivo Continuous Hemofiltration Model to Describe the Adsorption and Elimination of Meropenem and Piperacillin?. <i>International Journal of Artificial Organs</i> , 2015, 38, 419-424.	0.7	13
351	Antibiotic dosing for multidrug-resistant pathogen pneumonia. <i>Current Opinion in Infectious Diseases</i> , 2017, 30, 231-239.	1.3	13
352	Valganciclovir Pharmacokinetics in Patients Receiving Oral Prophylaxis Following Kidney Transplantation and Model-Based Predictions of Optimal Dosing Regimens. <i>Clinical Pharmacokinetics</i> , 2018, 57, 1399-1405.	1.6	13
353	Cerebrospinal fluid penetration of very high-dose meropenem: a case report. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2018, 17, 47.	1.7	13
354	Vancomycin Population Pharmacokinetics in Critically Ill Adults During Sustained Low-Efficiency Dialysis. <i>Clinical Pharmacokinetics</i> , 2020, 59, 327-334.	1.6	13
355	Oral Fosfomycin Efficacy with Variable Urinary Exposures following Single and Multiple Doses against Enterobacterales : the Importance of Heteroresistance for Growth Outcome. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	13
356	Precision dosing software to optimize antimicrobial dosing: a systematic search and follow-up survey of available programs. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1211-1224.	2.8	13
357	Antimicrobial stewardship of $\beta$ -lactams in intensive care units. <i>Expert Review of Anti-Infective Therapy</i> , 2014, 12, 581-595.	2.0	12
358	Integrated pharmacokinetic-pharmacodynamic modelling to evaluate antimicrobial prophylaxis in abdominal surgery. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2902-2908.	1.3	12
359	New paradigm for rapid achievement of appropriate therapy in special populations: coupling antibiotic dose optimization rapid microbiological methods. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 693-708.	1.5	12
360	Analysis of capillary microsamples obtained from a skin-prick to measure vancomycin concentrations as a valid alternative to conventional sampling: A bridging study. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 169, 288-292.	1.4	12

#	ARTICLE	IF	CITATIONS
361	Pharmacodynamic evaluation of intermittent versus extended and continuous infusions of piperacillin/tazobactam in a hollow-fibre infection model against <i>Klebsiella pneumoniae</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2633-2640.	1.3	12
362	Pharmacokinetics and pharmacodynamics of anti-infective agents during continuous veno-venous hemofiltration in critically ill patients: Lessons learned from an ancillary study of the IVOIRE trial. <i>Journal of Translational Internal Medicine</i> , 2019, 7, 155-169.	1.0	12
363	Kidney transplant recipientâ€™s perceptions of blood testing through microsampling and venepuncture. <i>Bioanalysis</i> , 2020, 12, 873-881.	0.6	12
364	Population pharmacokinetics of cefepime in critically ill patients receiving extracorporeal membrane oxygenation (an ASAP ECMO study). <i>International Journal of Antimicrobial Agents</i> , 2021, 58, 106466.	1.1	12
365	Effect of intravenous GLutamine supplementation IN Trauma patients receiving enteral nutrition study protocol (GLINT Study): a prospective, blinded, randomised, placebo-controlled clinical trial. <i>BMJ Open</i> , 2011, 1, e000334-e000334.	0.8	11
366	A national survey of renal replacement therapy prescribing practice for acute kidney injury in <sc>Malaysian intensive care units. <i>Nephrology</i> , 2014, 19, 507-512.	0.7	11
367	Stability of Antibiotics for Intraperitoneal Administration in Extraneal 7.5% Icodextrin Peritoneal Dialysis Bags (Stab Study). <i>Peritoneal Dialysis International</i> , 2016, 36, 421-426.	1.1	11
368	Population Pharmacokinetics of Doripenem in Critically Ill Patients with Sepsis in a Malaysian Intensive Care Unit. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 206-214.	1.4	11
369	The effect of pharmacists on ward rounds measured by the STOPP/START tool in a specialized geriatric unit. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2017, 42, 178-184.	0.7	11
370	Predictive performance of a gentamicin population pharmacokinetic model in two western populations of critically ill patients. <i>International Journal of Antimicrobial Agents</i> , 2018, 52, 218-225.	1.1	11
371	A validated LC-MSMS method for the simultaneous quantification of meropenem and vaborbactam in human plasma and renal replacement therapy effluent and its application to a pharmacokinetic study. <i>Analytical and Bioanalytical Chemistry</i> , 2019, 411, 7831-7840.	1.9	11
372	The Australasian COVID-19 Trial (ASCOT) to assess clinical outcomes in hospitalised patients with SARS-CoV-2 infection (COVID-19) treated with lopinavir/ritonavir and/or hydroxychloroquine compared to standard of care: A structured summary of a study protocol for a randomised controlled trial. <i>Trials</i> , 2020, 21, 646.	0.7	11
373	Development of Population and Bayesian Models for Applied Use in Patients Receiving Cefepime. <i>Clinical Pharmacokinetics</i> , 2020, 59, 1027-1036.	1.6	11
374	Optimization of Ganciclovir use in allogeneic hematopoietic cell transplant recipients â€” the role of therapeutic drug monitoring. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 707-718.	2.0	11
375	Standard of practice in intensive care for pharmacy services. <i>Journal of Pharmacy Practice and Research</i> , 2021, 51, 165-183.	0.5	11
376	Rescuing Tetracycline Class Antibiotics for the Treatment of Multidrug-Resistant <i>Acinetobacter baumannii</i> Pulmonary Infection. <i>MBio</i> , 2022, 13, e0351721.	1.8	11
377	How should we dose antibiotics for pneumonia in the ICU?. <i>Current Opinion in Infectious Diseases</i> , 2013, 26, 189-195.	1.3	10
378	Antibiotic dosing in obesity: a BIG challenge. <i>Critical Care</i> , 2016, 20, 240.	2.5	10

#	ARTICLE	IF	CITATIONS
379	Pharmacokinetic/Pharmacodynamics-Optimized Antimicrobial Therapy in Patients with Hospital-Acquired Pneumonia/Ventilator-Associated Pneumonia. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2017, 38, 271-286.	0.8	10
380	An Integrated Dialysis Pharmacometric (IDP) Model to Evaluate the Pharmacokinetics in Patients Undergoing Renal Replacement Therapy. <i>Pharmaceutical Research</i> , 2020, 37, 96.	1.7	10
381	Optimising Treatment Outcomes for Children and Adults Through Rapid Genome Sequencing of Sepsis Pathogens. A Study Protocol for a Prospective, Multi-Centre Trial (DIRECT). <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 667680.	1.8	10
382	Dose optimisation of antibiotics used for meningitis. <i>Current Opinion in Infectious Diseases</i> , 2021, Publish Ahead of Print, 581-590.	1.3	10
383	Therapeutic Drug Monitoring of Antibiotic Drugs in Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis: A Critical Review. <i>Therapeutic Drug Monitoring</i> , 2022, 44, 86-102.	1.0	10
384	Political Ecology. <i>Cambridge Encyclopedia of Anthropology</i> , 2020, , .	0.7	10
385	Pharmacodynamics of ceftriaxone for the treatment of methicillinâ€susceptible <i>Staphylococcus aureus</i> : is it a viable treatment option?. <i>International Journal of Antimicrobial Agents</i> , 2022, 59, 106537.	1.1	10
386	Pandoraâ€™s box: Paxlovid, prescribing, pharmacists and pandemic. <i>Journal of Pharmacy Practice and Research</i> , 2022, 52, 1-4.	0.5	10
387	A protocol for a phase 3 multicentre randomised controlled trial of continuous versus intermittent Î²-lactam antibiotic infusion in critically ill patients with sepsis: BLING III. <i>Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine</i> , 2019, 21, 63-68.	0.0	10
388	Optimising intraperitoneal gentamicin dosing in peritoneal dialysis patients with peritonitis (GIPD) study. <i>BMC Nephrology</i> , 2009, 10, 42.	0.8	9
389	An UHPLCâ€“MS/MS method for the simultaneous determination of ampicillin and sulbactam in human plasma and urine. <i>Bioanalysis</i> , 2015, 7, 2311-2319.	0.6	9
390	Evidence of clinical response and stability of Ceftolozane/Tazobactam used to treat a carbapenem-resistant <i>Pseudomonas Aeruginosa</i> lung abscess on an outpatient antimicrobial program. <i>International Journal of Antimicrobial Agents</i> , 2018, 51, 941-942.	1.1	9
391	Risk factors for multidrugâ€resistant <i>G&lt;/sc&gt;G&lt;/sc&gt;</i> ramâ€negative infection in burn patients. <i>ANZ Journal of Surgery</i> , 2018, 88, 480-485.	0.3	9
392	Pharmacokinetics of Ceftolozane-Tazobactam during Prolonged Intermittent Renal Replacement Therapy. <i>Chemotherapy</i> , 2018, 63, 203-206.	0.8	9
393	Effect of plasmapheresis on ATG (Thymoglobulin) clearance prior to adoptive T cell transfer. <i>Bone Marrow Transplantation</i> , 2019, 54, 2110-2116.	1.3	9
394	A Systematic Review of Studies Reporting Antibiotic Pharmacokinetic Data in the Cerebrospinal Fluid of Critically Ill Patients with Uninflamed Meninges. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 65, .	1.4	9
395	Non-polymyxin-based combinations as potential alternatives in treatment against carbapenem-resistant <i>Acinetobacter baumannii</i> infections. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106115.	1.1	9
396	Population Pharmacokinetics of Piperacillin and Tazobactam in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation: an ASAP ECMO Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0143821.	1.4	9

#	ARTICLE	IF	CITATIONS
397	Cefepime Precision Dosing Tool: from Standard to Precise Dose Using Nonparametric Population Pharmacokinetics. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0204621.	1.4	9
398	Introduction to the updated Australasian consensus guidelines for the management of invasive fungal disease and use of antifungal agents in the haematology/oncology setting, 2021. <i>Internal Medicine Journal</i> , 2021, 51, 3-17.	0.5	9
399	Variable ganciclovir concentrations in a critically ill patient receiving continuous renal replacement therapy and plasma exchange?. <i>International Journal of Antimicrobial Agents</i> , 2014, 43, 570-571.	1.1	8
400	Pharmacokinetics of fluconazole in critically ill patients with acute kidney injury receiving sustained low-efficiency dialysis. <i>International Journal of Antimicrobial Agents</i> , 2015, 45, 192-195.	1.1	8
401	Even high-dose extended infusions may not yield desired concentrations of $\beta$ -lactams: the value of therapeutic drug monitoring. <i>Infectious Diseases</i> , 2015, 47, 739-742.	1.4	8
402	What's new in pharmacokinetics of antimicrobials in AKI and RRT?. <i>Intensive Care Medicine</i> , 2017, 43, 904-906.	3.9	8
403	Evaluation of pharmacokinetic/pharmacodynamic and clinical outcomes with 6-hourly empiric piperacillin-tazobactam dosing in hematological malignancy patients with febrile neutropenia. <i>Journal of Infection and Chemotherapy</i> , 2019, 25, 503-508.	0.8	8
404	Development and validation of LC-MS/MS methods to measure tobramycin and lincomycin in plasma, microdialysis fluid and urine: application to a pilot pharmacokinetic research study. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 274-284.	1.4	8
405	Effectiveness of Vancomycin Dosing Guided by Therapeutic Drug Monitoring in Adult Patients Receiving Extracorporeal Membrane Oxygenation. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	8
406	Evaluation of target attainment of oral posaconazole suspension in immunocompromised children. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 726-729.	1.3	8
407	Provider perspectives on beta-lactam therapeutic drug monitoring programs in the critically ill: a protocol for a multicenter mixed-methods study. <i>Implementation Science Communications</i> , 2021, 2, 34.	0.8	8
408	Semimechanistic Pharmacokinetic/Pharmacodynamic Modeling of Fosfomycin and Sulbactam Combination against Carbapenem-Resistant <i>Acinetobacter baumannii</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	8
409	Personalized $\beta$ -lactam dosing in patients with coronavirus disease 2019 (COVID-19) and pneumonia. <i>Medicine (United States)</i> , 2021, 100, e26253.	0.4	8
410	A meta-analysis of protein binding of flucloxacillin in healthy volunteers and hospitalized patients. <i>Clinical Microbiology and Infection</i> , 2022, 28, 446.e1-446.e7.	2.8	8
411	Individualized precision dosing approaches to optimize antimicrobial therapy in pediatric populations. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 1383-1399.	1.3	8
412	A survey of antibiotic prescribing practices in Australian and New Zealand intensive care units. <i>Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine</i> , 2010, 12, 162-70.	0.0	8
413	Population Pharmacokinetics and Dosing Simulations of Ceftriaxone in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (An ASAP ECMO Study). <i>Clinical Pharmacokinetics</i> , 2022, 61, 847-856.	1.6	8
414	Multicenter Population Pharmacokinetic Study of Unbound Ceftriaxone in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, e0218921.	1.4	8



#	ARTICLE	IF	CITATIONS
415	Ganciclovir pharmacokinetics and suggested dosing in continuous venovenous haemodiafiltration. <i>International Journal of Antimicrobial Agents</i> , 2011, 37, 90-92.	1.1	7
416	The pharmacokinetics of cefazolin in patients undergoing elective & semi-elective abdominal aortic aneurysm open repair surgery. <i>BMC Anesthesiology</i> , 2011, 11, 5.	0.7	7
417	Can optimal drug dosing during ECMO improve outcomes?. <i>Intensive Care Medicine</i> , 2013, 39, 2237-2237.	3.9	7
418	Pharmacokinetics of Intraperitoneal Cefalothin and Cefazolin in Patients Being Treated for Peritoneal Dialysis-Associated Peritonitis. <i>Peritoneal Dialysis International</i> , 2016, 36, 415-420.	1.1	7
419	A research pathway for the study of the delivery and disposition of nebulised antibiotics: an incremental approach from in vitro to large animal models. <i>Intensive Care Medicine Experimental</i> , 2018, 6, 17.	0.9	7
420	Determining the editorial policy of Anaesthesia Critical Care and Pain Medicine (ACCPM). <i>Anaesthesia, Critical Care &amp; Pain Medicine</i> , 2018, 37, 299-301.	0.6	7
421	A pharmacokinetic case study of intravenous posaconazole in a critically ill patient with hypoalbuminaemia receiving continuous venovenous haemodiafiltration. <i>International Journal of Antimicrobial Agents</i> , 2018, 52, 506-509.	1.1	7
422	In-vitro adsorption and sieving coefficient of ticarcillin-clavulanate during continuous haemofiltration. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 261-264.	1.1	7
423	Pharmacokinetics of Enteric-Coated Mycophenolate Sodium in Lupus Nephritis (POEMSLUN). <i>Therapeutic Drug Monitoring</i> , 2019, 41, 703-713.	1.0	7
424	Pharmacodynamic Evaluation of Plasma and Epithelial Lining Fluid Exposures of Amikacin against <i>Pseudomonas aeruginosa</i> in a Dynamic <i>In Vitro</i> Hollow-Fiber Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	7
425	Clinically Relevant Epithelial Lining Fluid Concentrations of Meropenem with Ciprofloxacin Provide Synergistic Killing and Resistance Suppression of Hypermutable <i>Pseudomonas aeruginosa</i> in a Dynamic Biofilm Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	7
426	Epidemiology of extended-spectrum $\beta$ -lactamase and metallo- $\beta$ -lactamase-producing <i>Escherichia coli</i> in South Asia. <i>Future Microbiology</i> , 2021, 16, 521-535.	1.0	7
427	Australian National Enterovirus Reference Laboratory annual report, 2018. <i>Communicable Diseases Intelligence</i> (2018), 2020, 44, .	0.3	7
428	Population Pharmacokinetics of Vancomycin in Critically Ill Adult Patients Receiving Extracorporeal Membrane Oxygenation (an ASAP ECMO Study). <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0137721.	1.4	7
429	Evaluation of low-volume plasma sampling for the analysis of meropenem in clinical samples. <i>Analytical and Bioanalytical Chemistry</i> , 2022, 414, 2155-2162.	1.9	7
430	Influence of PEGylated porous silicon nanoparticles on permeation and efflux of an orally administered antibiotic. <i>Materials Today Advances</i> , 2022, 13, 100210.	2.5	7
431	Population pharmacokinetics and toxicodynamics of continuously infused linezolid in critically ill patients. <i>International Journal of Antimicrobial Agents</i> , 2022, 59, 106572.	1.1	7
432	Public Health Response to Imported Case of Poliomyelitis, Australia, 2007. <i>Emerging Infectious Diseases</i> , 2009, 15, 1733-1737.	2.0	6

#	ARTICLE	IF	CITATIONS
433	Oral poliovirus vaccine type 3 from a patient with transverse myelitis is neurovirulent in a transgenic mouse model. <i>Journal of Clinical Virology</i> , 2009, 44, 268-271.	1.6	6
434	Tissue Distribution of Beta-Lactam Antibiotics: Continuous versus Bolus Dosing. <i>Journal of Pharmacy Practice and Research</i> , 2009, 39, 219-222.	0.5	6
435	Does Appropriate Antibiotic Therapy Mean Only Adequate Spectrum and Timing?*. <i>Critical Care Medicine</i> , 2015, 43, 1773-1774.	0.4	6
436	Influence of sustained low-efficiency diafiltration (SLED-f) on interstitial fluid concentrations of fluconazole in a critically ill patient: Use of microdialysis. <i>International Journal of Antimicrobial Agents</i> , 2015, 46, 121-124.	1.1	6
437	Tigecycline use in the outpatient parenteral antibiotic therapy setting. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2016, 35, 1673-1677.	1.3	6
438	We need to optimize piperacillin-tazobactam dosing in critically ill patients—but how?. <i>Critical Care</i> , 2016, 20, 163.	2.5	6
439	Recovery rates of combination antibiotic therapy using in vitro microdialysis simulating in vivo conditions. <i>Journal of Pharmaceutical Analysis</i> , 2018, 8, 407-412.	2.4	6
440	Pharmacokinetics of Benzylpenicillin (Penicillin G) during Prolonged Intermittent Renal Replacement Therapy. <i>Chemotherapy</i> , 2019, 64, 17-21.	0.8	6
441	Population Pharmacokinetics of Periarticular Ketorolac in Adult Patients Undergoing Total Hip or Total Knee Replacement Surgery. <i>Anesthesia and Analgesia</i> , 2019, 129, 701-708.	1.1	6
442	Nebulized Tranexamic Acid Therapy for Hemoptysis Associated with Submassive Pulmonary Embolism. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2020, 33, 12-14.	0.7	6
443	$\beta$ -lactam dosing strategies: Think before you push. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106151.	1.1	6
444	Vancomycin Serum Concentration after 48 h of Administration: A 3-Years Survey in an Intensive Care Unit. <i>Antibiotics</i> , 2020, 9, 793.	1.5	6
445	What Are the Predictors for Achieving Therapeutic Levetiracetam Serum Concentrations in Adult Neurological Patients?. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 626-630.	1.0	6
446	Semi-mechanistic PK/PD modelling of meropenem and sulbactam combination against carbapenem-resistant strains of <i>Acinetobacter baumannii</i> . <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 1943-1952.	1.3	6
447	Microsampling to support pharmacokinetic clinical studies in pediatrics. <i>Pediatric Research</i> , 2022, 91, 1557-1561.	1.1	6
448	A Systematic Review of the Clinical Pharmacokinetics, Pharmacodynamics and Toxicodynamics of Ganciclovir/Valganciclovir in Allogeneic Haematopoietic Stem Cell Transplant Patients. <i>Clinical Pharmacokinetics</i> , 2021, 60, 727-739.	1.6	6
449	Editorial: Principles of ethical prescribing for self and others: hydroxychloroquine in the COVID-19 pandemic. <i>Australian Prescriber</i> , 2020, 43, 76-77.	0.5	6
450	Oral fosfomycin activity against <i>Klebsiella pneumoniae</i> in a dynamic bladder infection in vitro model. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 1324-1333.	1.3	6

#	ARTICLE	IF	CITATIONS
451	Clearance of intravenous 5-fluorocytosine during continuous venovenous haemodiafiltration in a patient with hepatosplenic candidiasis. <i>International Journal of Antimicrobial Agents</i> , 2009, 34, 383-384.	1.1	5
452	Electron microscope detection of an endogenous infection of retrovirus-like particles in L20B cells. <i>Microscopy (Oxford, England)</i> , 2013, 62, 485-486.	0.7	5
453	Population pharmacokinetics of intravenous paracetamol in critically ill patients with traumatic brain injury. <i>Journal of Critical Care</i> , 2018, 47, 15-20.	1.0	5
454	The pharmacokinetics of meropenem and piperacillin-tazobactam during sustained low efficiency haemodiafiltration (SLED-HDF). <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 239-247.	0.8	5
455	Pharmacodynamic Analysis of Meropenem and Fosfomycin Combination Against Carbapenem-Resistant <i>Acinetobacter baumannii</i> in Patients with Normal Renal Clearance: Can It Be a Treatment Option?. <i>Microbial Drug Resistance</i> , 2021, 27, 546-552.	0.9	5
456	Antimicrobial pharmacokinetics and preclinical in vitro models to support optimized treatment approaches for uncomplicated lower urinary tract infections. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 271-295.	2.0	5
457	Pharmacokinetics of fluconazole and ganciclovir as combination antimicrobial chemotherapy on ECMO: a case report. <i>International Journal of Antimicrobial Agents</i> , 2021, 58, 106431.	1.1	5
458	Indonesian healthcare providers' perceptions and attitude on antimicrobial resistance, prescription and stewardship programs. <i>Future Microbiology</i> , 2022, 17, 363-375.	1.0	5
459	Treatment of ventilator-associated pneumonia due to carbapenem-resistant Gram-negative bacteria with novel agents: a contemporary, multidisciplinary ESGCIP perspective. <i>Expert Review of Anti-Infective Therapy</i> , 2022, 20, 963-979.	2.0	5
460	Plasma and Cerebrospinal Fluid Population Pharmacokinetics of Meropenem in Neurocritical Care Patients: a Prospective Two-Center Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, .	1.4	5
461	Echovirus 19 associated with a case of acute flaccid paralysis. <i>Journal of Paediatrics and Child Health</i> , 2013, 49, E239-42.	0.4	4
462	Isolation and Characterization of Poliovirus in Cell Culture Systems. <i>Methods in Molecular Biology</i> , 2016, 1387, 29-53.	0.4	4
463	Antibiotic Dosing In Critically Ill Patients Receiving Renal Replacement Therapy. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 497-499.	1.3	4
464	Differences in suppression of regrowth and resistance despite similar initial bacterial killing for meropenem and piperacillin/tazobactam against <i>Pseudomonas aeruginosa</i> and <i>Escherichia coli</i> . <i>Diagnostic Microbiology and Infectious Disease</i> , 2018, 91, 69-76.	0.8	4
465	Characterisation of 40 mg/ml and 100 mg/ml tobramycin formulations for aerosol therapy with adult mechanical ventilation. <i>Pulmonary Pharmacology and Therapeutics</i> , 2018, 50, 93-99.	1.1	4
466	Antimicrobial therapy during ECMO—customised dosing with therapeutic drug monitoring: The way to go?. <i>Anaesthesia, Critical Care &amp; Pain Medicine</i> , 2019, 38, 451-453.	0.6	4
467	Pharmacokinetics of Total and Unbound Cefazolin during Veno-Arterial Extracorporeal Membrane Oxygenation: A Case Report. <i>Chemotherapy</i> , 2019, 64, 115-118.	0.8	4
468	Amoxicillin-Clavulanate Dosing in the Intensive Care Unit: The Additive Effect of Renal Replacement Therapy in a Patient with Normal Kidney Function. <i>Chemotherapy</i> , 2019, 64, 173-176.	0.8	4

#	ARTICLE	IF	CITATIONS
469	Pharmacokinetics of Micafungin in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis With High Cutoff Membranes. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 376-382.	1.0	4
470	Ticarcillin and piperacillin adsorption on to polyethersulfone haemodiafilter membranes in an ex-vivo circuit. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106058.	1.1	4
471	Comparative Plasma Pharmacokinetics of Ceftriaxone and Ertapenem in Normoalbuminemia, Hypoalbuminemia, and Albumin Replacement in a Sheep Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	4
472	Letter to the Editor regarding: Ceftriaxone exposure in patients undergoing extracorporeal membrane oxygenation. <i>International Journal of Antimicrobial Agents</i> , 2021, 57, 106326.	1.1	4
473	Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Drug Treatment of Non-Tuberculous Mycobacteria in Cystic Fibrosis. <i>Clinical Pharmacokinetics</i> , 2021, 60, 1081-1102.	1.6	4
474	Prospective Cohort Study of Micafungin Population Pharmacokinetic Analysis in Plasma and Peritoneal Fluid in Septic Patients with Intra-abdominal Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0230720.	1.4	4
475	Population Pharmacokinetics of Vancomycin and Meropenem in Pediatric Extracorporeal Membrane Oxygenation Support. <i>Frontiers in Pharmacology</i> , 2021, 12, 709332.	1.6	4
476	Evolutionary changes in the capsid P2 region of Australian strains of the norovirus GII.Pe_GII.4. <i>Journal of Medical Microbiology</i> , 2017, 66, 1014-1022.	0.7	4
477	Australian National Enterovirus Reference Laboratory annual report, 2015. <i>Communicable Diseases Intelligence</i> (2018), 2020, 44, .	0.3	4
478	A validated LC-MS/MS method for the simultaneous quantification of the novel combination antibiotic, ceftolozane-tazobactam, in plasma (total and unbound), CSF, urine and renal replacement therapy effluent: application to pilot pharmacokinetic studies. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 921-933.	1.4	4
479	Effect of Different Piperacillin-Tazobactam Dosage Regimens on Synergy of the Combination with Tobramycin against <i>Pseudomonas aeruginosa</i> for the Pharmacokinetics of Critically Ill Patients in a Dynamic Infection Model. <i>Antibiotics</i> , 2022, 11, 101.	1.5	4
480	Incremental research approach to describing the pharmacokinetics of ciprofloxacin during extracorporeal membrane oxygenation. <i>Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine</i> , 2017, 19, 8-14.	0.0	4
481	Population Pharmacokinetics of Intraperitoneal Gentamicin and the Impact of Varying Dwell Times on Pharmacodynamic Target Attainment in Patients with Acute Peritonitis Undergoing Peritoneal Dialysis. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0167921.	1.4	4
482	Hospital-Based Antimicrobial Stewardship Programs Used in Low- and Middle-Income Countries: A Scoping Review. <i>Microbial Drug Resistance</i> , 2022, 28, 566-584.	0.9	4
483	Evaluating Mono- and Combination Therapy of Meropenem and Amikacin against <i>Pseudomonas aeruginosa</i> Bacteremia in the Hollow-Fiber Infection Model. <i>Microbiology Spectrum</i> , 2022, 10, e0052522.	1.2	4
484	Population pharmacokinetics and dose optimization of intravenous levofloxacin in hospitalized adult patients. <i>Scientific Reports</i> , 2022, 12, .	1.6	4
485	Plasma and Interstitial Fluid Pharmacokinetics of Prophylactic Cefazolin in Elective Bariatric Surgery Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 0, , .	1.4	4
486	Midazolam Metabolism: Implications for Individualised Dosing?. <i>Journal of Pharmacy Practice and Research</i> , 2009, 39, 198-201.	0.5	3

#	ARTICLE	IF	CITATIONS
487	Editorial [Hot Topic: Relevance of Pharmacokinetics to Antibiotic Dosing in Critically Ill Patients (Guest Editor: Jason A. Roberts)]. <i>Current Pharmaceutical Biotechnology</i> , 2011, 12, 1981-1982.	0.9	3
488	Amikacin dosing in the ICU: we now know more, but still not enough. <i>Intensive Care Medicine</i> , 2014, 40, 1033-1035.	3.9	3
489	Microbiologic clearance following transition from standard infusion piperacillin-tazobactam to extended-infusion for persistent Gram-negative bacteremia and possible endocarditis: A case report and review of the literature. <i>Journal of Infection and Chemotherapy</i> , 2015, 21, 742-746.	0.8	3
490	The challenge of quantifying and managing pharmacokinetic variability of beta-lactams in the critically ill. <i>Anaesthesia, Critical Care &amp; Pain Medicine</i> , 2020, 39, 27-29.	0.6	3
491	The role of antibiotic pharmacokinetic studies performed post-licensing. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106165.	1.1	3
492	Ceftriaxone dosing in patients admitted from the emergency department with sepsis. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 207-214.	0.8	3
493	A Loading Micafungin Dose in Critically Ill Patients Undergoing Continuous Venovenous Hemofiltration or Continuous Venovenous Hemodiafiltration: A Population Pharmacokinetic Analysis. <i>Therapeutic Drug Monitoring</i> , 2021, 43, 747-755.	1.0	3
494	Epidemiology and Microbiology of Severe Community-Acquired Pneumonia in Central Australia: A Retrospective Study. <i>Internal Medicine Journal</i> , 2020, , .	0.5	3
495	Australian National Enterovirus Reference Laboratory annual report, 2019. <i>Communicable Diseases Intelligence</i> (2018), 0, 44, .	0.3	3
496	A protocol for a multicentre randomised controlled trial of continuous beta-lactam infusion compared with intermittent beta-lactam dosing in critically ill patients with severe sepsis: the BLING II study. <i>Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine</i> , 2013, 15, 179-85.	0.0	3
497	Is Dosing of Ethambutol as Part of a Fixed-Dose Combination Product Optimal for Mechanically Ventilated ICU Patients with Tuberculosis? A Population Pharmacokinetic Study. <i>Antibiotics</i> , 2021, 10, 1559.	1.5	3
498	Caspofungin Population Pharmacokinetic Analysis in Plasma and Peritoneal Fluid in Septic Patients with Intra-Abdominal Infections: A Prospective Cohort Study. <i>Clinical Pharmacokinetics</i> , 2022, 61, 673-686.	1.6	3
499	Population pharmacokinetics of ciprofloxacin in critically ill patients receiving extracorporeal membrane oxygenation (an ASAP ECMO study). <i>Anaesthesia, Critical Care &amp; Pain Medicine</i> , 2022, , 101080.	0.6	3
500	Pharmacodynamic evaluation of piperacillin/tazobactam versus meropenem against extended-spectrum $\beta$ -lactamase-producing and non-producing <i>Escherichia coli</i> clinical isolates in a hollow-fibre infection model. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 2448-2455.	1.3	3
501	A Protocol for the Pharmacokinetics of Enteric Coated Mycophenolate Sodium in Lupus Nephritis (POEMSLUN): an open-label, randomised controlled trial. <i>BMJ Open</i> , 2013, 3, e003511.	0.8	2
502	Reply to Rhodes et al. <i>Clinical Infectious Diseases</i> , 2014, 59, 907-908.	2.9	2
503	Antibiotic dose optimization in critically ill patients. <i>Medicina Intensiva (English Edition)</i> , 2015, 39, 563-572.	0.1	2
504	Erratum to "œls inhaled prophylactic heparin useful for prevention and management of pneumonia in ventilated ICU patients? The IPHIVAP investigators of the Australian and New Zealand Intensive Care Society Clinical Trials Group" <i>Journal of Critical Care</i> 34 (2016) 95-102. <i>Journal of Critical Care</i> , 2016, 35, 230.	1.0	2

#	ARTICLE	IF	CITATIONS
505	Are new gentamicin dosing guidelines suitable for achieving target concentrations in patients with sepsis and septic shock?. <i>Anaesthesia, Critical Care &amp; Pain Medicine</i> , 2016, 35, 311-312.	0.6	2
506	Population pharmacokinetics of ticarcillin in critically ill patients receiving extended daily diafiltration. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 351-355.	1.1	2
507	Pharmacokinetics of flucloxacillin during prolonged intermittent renal replacement therapy in a 76-year-old man. <i>Journal of Chemotherapy</i> , 2019, 31, 419-423.	0.7	2
508	Low levels of salicylic acid and salicyluric acid are present in synovial fluid of patients taking aspirin at the time of knee arthroplasty surgery. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2020, 47, 1635-1637.	0.9	2
509	Impact of the Epithelial Lining Fluid Milieu on Amikacin Pharmacodynamics Against <i>Pseudomonas aeruginosa</i> . <i>Drugs in R and D</i> , 2021, 21, 203-215.	1.1	2
510	Pharmacodynamic Evaluation of a Single Dose versus a 24-Hour Course of Multiple Doses of Cefazolin for Surgical Prophylaxis. <i>Antibiotics</i> , 2021, 10, 602.	1.5	2
511	Development and validation of a UHPLC-MS/MS method to measure cefotaxime and metabolite desacetylcefotaxime in blood plasma: a pilot study suitable for capillary microsampling in critically ill children. <i>Analytical and Bioanalytical Chemistry</i> , 2021, 413, 4483-4491.	1.9	2
512	Standard of practice in infectious diseases for pharmacy services. <i>Journal of Pharmacy Practice and Research</i> , 2021, 51, 247-264.	0.5	2
513	Antibiotic pharmacokinetics/pharmacodynamics: where are we heading?. <i>International Journal of Antimicrobial Agents</i> , 2021, 58, 106369.	1.1	2
514	Population Pharmacokinetics Analysis of Amikacin Initial Dosing Regimen in Elderly Patients. <i>Antibiotics</i> , 2021, 10, 100.	1.5	2
515	Antibiotic Dosing During Extracorporeal Membrane Oxygenation. , 2018, , 151-171.		2
516	Dose Adjustment and Pharmacodynamic Considerations for Antibiotics in Severe Sepsis and Septic Shock. , 2008, , 97-136.		2
517	Antibiotic Pharmacodynamics. , 2018, , 17-29.		2
518	Linguistic and cultural adaptation to the Portuguese language of antimicrobial dose adjustment software. <i>Einstein (Sao Paulo, Brazil)</i> , 2020, 18, eAO5023.	0.3	2
519	<i>In vitro</i> effect of synovial fluid from patients undergoing arthroplasty surgery on MRSA biofilm formation. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 1041-1044.	1.3	2
520	Annual report of the Australian National Poliovirus Reference Laboratory, 2006. <i>Communicable Diseases Intelligence Quarterly Report</i> , 2007, 31, 263-9.	0.6	2
521	Editorial: Oral antivirals for mild-moderate COVID-19: a panacea or a logistical and clinical conundrum?. <i>Australian Prescriber</i> , 2022, 45, 67-68.	0.5	2
522	Therapeutic Drug Monitoring and Prolonged Infusions of Ceftolozane/Tazobactam for MDR/XDR <i>Pseudomonas aeruginosa</i> Infections: An Observational Study. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 0, , .	0.6	2

#	ARTICLE	IF	CITATIONS
523	Continuous Infusion of Time-dependent Antibiotics. <i>Clinical Pulmonary Medicine</i> , 2008, 15, 167-172.	0.3	1
524	Optimizing Antibiotic Use in the Intensive Care Unit. <i>Clinical Pulmonary Medicine</i> , 2010, 17, 162-169.	0.3	1
525	Therapeutic drug monitoring of antibiotics – Author's reply. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 1181.	4.6	1
526	The authors reply. <i>Critical Care Medicine</i> , 2015, 43, e154-e155.	0.4	1
527	Pharmacodynamic Considerations in Critically Ill Patients. <i>Methods in Pharmacology and Toxicology</i> , 2016, , 537-560.	0.1	1
528	A validated UHPLC-MS/MS method for the measurement of riluzole in plasma and myocardial tissue samples. <i>Biomedical Chromatography</i> , 2017, 31, e4030.	0.8	1
529	Pharmacokinetic and Pharmacodynamic Tools to Increase Efficacy. , 2017, , 85-98.		1
530	Beta-Lactam Therapeutic Drug Monitoring in the Critically Ill Children. <i>Critical Care Medicine</i> , 2018, 46, 335-337.	0.4	1
531	Re: "Is a randomized trial of a short course of aminoglycoside added to $\beta$ -lactam antibiotics for empirical treatment in critically ill patients with sepsis justified?" Pharmacokinetic/pharmacodynamic considerations. <i>Clinical Microbiology and Infection</i> , 2018, 24, 666-667.	2.8	1
532	Attainment of therapeutic vancomycin level within the first 24h: Authors' response. <i>Critical Care</i> , 2019, 23, 354.	2.5	1
533	Pharmacokinetics of Sulfamethoxazole and Trimethoprim During Venovenous Extracorporeal Membrane Oxygenation: A Case Report. <i>Pharmacotherapy</i> , 2020, 40, 713-717.	1.2	1
534	The risks of medical complacency towards poliomyelitis. <i>Medical Journal of Australia</i> , 2020, 213, 61.	0.8	1
535	Comparative lung distribution of radiolabeled tobramycin between nebulized and intravenous administration in a mechanically-ventilated ovine model, an observational study.. <i>International Journal of Antimicrobial Agents</i> , 2021, 57, 106232.	1.1	1
536	Antimicrobial dosing in prolonged intermittent renal replacement therapy: a systematic review. <i>Journal of Pharmacy Practice and Research</i> , 2021, 51, 106-120.	0.5	1
537	The impact of pharmacist-led antifungal stewardship interventions in the hospital setting: a systematic review. <i>Journal of Pharmacy Practice and Research</i> , 2021, 51, 90-105.	0.5	1
538	Applying Antimicrobial Pharmacokinetic Principles for Complex Patients: Critically Ill Adult Patients Receiving Extracorporeal Membrane Oxygenation and Renal Replacement Therapy. <i>Current Infectious Disease Reports</i> , 2021, 23, 1.	1.3	1
539	New approaches to enterovirus identification. <i>Microbiology Australia</i> , 2010, 31, 138.	0.1	1
540	Australian National Enterovirus Reference Laboratory annual report, 2016. <i>Communicable Diseases Intelligence</i> (2018), 2020, 44, .	0.3	1

#	ARTICLE	IF	CITATIONS
541	Pharmacokinetics of Amoxicillin and Cefepime During Prolonged Intermittent Renal Replacement Therapy: A Case Report. , 0, , 78-83.		1
542	Innovation in microsampling for therapeutic drug monitoring of gentamicin in neonates: a proof-of-concept study. International Journal of Antimicrobial Agents, 2022, 59, 106513.	1.1	1
543	Population Pharmacokinetic Model of Piperacillin in Critically Ill Patients and Describing Interethnic Variation Using External Validation. Antibiotics, 2022, 11, 434.	1.5	1
544	Perioperative cefazolin prophylaxis in paediatric cardiac surgery: a prospective, cohort study. Annals of Thoracic Surgery, 2022, , .	0.7	1
545	Optimal dosing of cefotaxime and desacetylcefotaxime for critically ill paediatric patients. Can we use microsampling?. Journal of Antimicrobial Chemotherapy, 2022, 77, 2227-2237.	1.3	1
546	Pharmacodynamic evaluation of piperacillin/tazobactam against extended-spectrum Î²-lactamase-producing versus non-producing Escherichia coli in a hollow-fibre infection model. International Journal of Antimicrobial Agents, 2022, , 106623.	1.1	1
547	Host-Bacteria Interactions in the Pathogenesis of Urinary Tract Infections. Pediatrics International, 1986, 28, 129-147.	0.2	0
548	Pharmacists Investigating Adverse Penicillin Responsesâ€”Pilot Study. Journal of Pharmacy Practice and Research, 2007, 37, 200-203.	0.5	0
549	Conclusions regarding the efficacy of treatments for neuroleptic malignant syndrome should be tempered given poor quality data, regardless of the analysis conducted. Critical Care, 2007, 11, 413.	2.5	0
550	Dose matters: Dose of antibiotics in the critically ill patient depends on the dose of renal replacement therapy. Critical Care Medicine, 2009, 37, 2491-2492.	0.4	0
551	Optimal Antibiotic Therapy in the Management of the Lung of the Critically Ill. Current Respiratory Medicine Reviews, 2010, 6, 253-263.	0.1	0
552	Australian Clinical Pharmacy Award 2012. Journal of Pharmacy Practice and Research, 2012, 42, 308-310.	0.5	0
553	How do I Adjust Antimicrobial Daily Dosage in Patients with MODS? A Pharmacist's Contribution. , 2012, , 199-217.		0
554	Reply to Soman et al. Clinical Infectious Diseases, 2013, 57, 323-324.	2.9	0
555	Meeting the challenges of advanced drug delivery in critical illness. Advanced Drug Delivery Reviews, 2014, 77, 1-2.	6.6	0
556	Polyene Antifungals. , 2016, , 109-115.		0
557	Aminoglycoside Dosing in Obesity. , 2016, , 39-44.		0
558	Appropriate Antimicrobial Therapy in Critically Ill Patients. Hot Topics in Acute Care Surgery and Trauma, 2018, , 319-342.	0.1	0



#	ARTICLE	IF	CITATIONS
559	The authors reply. <i>Critical Care Medicine</i> , 2018, 46, e725-e726.	0.4	0
560	A Robust Statistical Approach to Analyse Population Pharmacokinetic Data in Critically Ill Patients Receiving Renal Replacement Therapy. <i>Clinical Pharmacokinetics</i> , 2019, 58, 263-270.	1.6	0
561	Narrative Study on Pharmacokinetics of Antibiotics among Critically Ill Patients: the Implication on the Pharmacokinetics-Pharmacodynamics Target Attainment. <i>Pharmaceutical Sciences and Research</i> , 2019, 6, .	0.5	0
562	Clinical Pharmacy Considerations in ICU. , 2019, , 849-865.		0
563	Enterovirus. , 2010, , 229-233.		0
564	The association of picornaviruses with gastroenteritis. <i>Microbiology Australia</i> , 2012, 33, 82.	0.1	0
565	Antibiotic Therapy of Pneumonia in Critical Care. <i>Current Respiratory Medicine Reviews</i> , 2012, 8, 228-238.	0.1	0
566	Software for dose adjustment of antimicrobials. Implications for plasma concentrations and practical limitations. <i>Einstein (Sao Paulo, Brazil)</i> , 2020, 18, eCE5858.	0.3	0
567	Australian National Enterovirus Reference Laboratory annual report, 2017. <i>Communicable Diseases Intelligence (2018)</i> , 2020, 44, .	0.3	0
568	Micafungin Population PK Analysis in Healthy and Septic Pigs: Can the Septic Porcine Model Predict the Micafungin PK in Septic Patients?. <i>Pharmaceutical Research</i> , 2021, 38, 1863-1871.	1.7	0
569	Physician drug prescribing preferences and availability for ventilation of patients with COVID-19. <i>Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine</i> , 2020, , .	0.0	0
570	Physician drug prescribing preferences and availability for ventilation of patients with COVID-19. <i>Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine</i> , 2020, 22, 271-274.	0.0	0
571	Pharmacokinetics of valganciclovir and voriconazole during prolonged intermittent renal replacement therapy in a lung transplant recipient. <i>Transplant Infectious Disease</i> , 2022, 24, .	0.7	0
572	Use of the Hollow-Fiber Infection Model to Measure the Effect of Combination Therapy of Septic Shock Exposures of Meropenem and Ciprofloxacin against Intermediate and Resistant <i>Pseudomonas aeruginosa</i> Clinical Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, , e0214021.	1.4	0
573	Vancomycin population pharmacokinetic modeling in children using Bayesian estimation and a Non Parametric Approach. <i>Brazilian Journal of Pharmaceutical Sciences</i> , 0, 58, .	1.2	0